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Abstract?
 
Background.  Schizophrenia is a severe, psychiatric illness with neurocognitive deficits as its 
major component, and affects about 1% of the world population. Improving impaired 
neurocognitive function is one of the pivotal treatment goals in this patient population. In 
the treatment of schizophrenia, only a partial treatment response is typically achieved with 
dopamine antagonists; i.e., “antipsychotics”. The antidepressant mirtazapine has a unique 
mechanism of action with, in theory, an ability to enhance neurocognition and provide 
added value to antipsychotic treatment. The pharmacological mechanism of action for this 
neurocognitive enhancing effect of mirtazapine is probably due its receptor- binding profile.  
 
Aims. This study explored whether or not adjunctive mirtazapine has the potential to 
improve neurocognitive performance and alleviate clinical symptoms in patients with 
schizophrenia who demonstrated a suboptimal treatment response to first-generation 
antipsychotics (FGAs). 
 
Study design and Patients. This study was a neurocognitive arm of a single-center, 
randomized, add-on, double-blinded, placebo-controlled study, which was carried out in the 
Karelian Republic, Petrozavodsk, Russia. Patients with schizophrenia or a depressive type 
schizoaffective disorder, according to the Diagnostic and Statistical Manual of Mental and 
Behavioral Disorders 4th edition (DSM-IV) criteria, who received stable doses of FGA with 
inadequate treatment response were enrolled into the trial. Twenty patients were assigned 
to mirtazapine and 21 to placebo. After a one-week single-blind placebo run-in period, the 
participants were randomized to receive either 30 mg of mirtazapine or the placebo every 
night at bedtime (QHS) in a double-blind fashion for 6 weeks. Subsequently, those who were 
eligible to continue  entered the following 6-week open-label phase, where they were 
treated with mirtazapine 30 mg QHS.   
 
Methods.  At study weeks 0, 6, and 12, a senior psychologist performed neuropsychological 
examinations to evaluate neurocognitive functioning. Verbal and visual memory, visuo-
spatial and executive functions, verbal fluency and both general mental and psychomotor 
speeds were assessed by commonly used, validated neuropsychological tests for different 
neurocognitive domains. Clinical examinations were conducted at week –1 (screening), week 
0 (baseline) and after 1, 2, 4, 6, 7, 8, 10, and 12 weeks of treatment. Within group and 
between group differences were analyzed on Modified Intent-to Treat (MITT) basis with Last 
Observations Carried Forward (LOCF).  
 
Results. After 6 weeks of treatment, 5/21 neurocognitive parameters (i.e. Wechsler Adult 
Intelligence Scale Revised (WAIS-R) Block Design, p=0.021; Wechsler Memory Scale (WMS) 
Logical Memory, p=0.044; WMS Logical Memory Delayed, p=0.044; Stroop Dots, p=0.044; 
Trail Making Test Part A (TMT-A), p=0.018) were improved with statistical significance in the 
mirtazapine group. In contrast, only 1 of the 21 parameters changed significantly (WMS 
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Logical Memory, p=0.039) in the placebo group. Add-on 6-week mirtazapine treatment was 
superior when compared with placebo in the neuropsychological domains of visuo-spatial 
ability and general mental speed/attentional control (Block Design mirtazapine group vs. 
placebo and Stroop dots mirtazapine group vs. placebo, p=0.044 for both comparisons). The 
enhancing effect on the Block Design-measured visuo-spatial functioning was mediated 
through changes in positive, depressive symptoms and parkinsonism-like side effects, but 
not via changes in negative symptoms. Moreover, higher doses of FGAs, longer duration of 
illness and lower initial Block Design scores predicted this effect. During the 6 weeks 
extension phase, individuals who continued mirtazapine treatment and those who were 
switched from placebo to mirtazapine showed significant improvements on several 
neurocognitive tests. Those who switched from placebo to open label mirtazapine treatment  
achieved similar results in the 6 following weeks as the mirtazapine group during their first 6 
weeks of mirtazapine treatment. From week 0 to week 12, the continuation group 
demonstrated improvements in 17/21 neurocognitive parameters, while the switch group 
improved in 8/21 of the measured parameters. Twelve weeks of mirtazapine treatment 
indicated an advantage over a shorter, 6-week mirtazapine treatment on Stroop Dots time 
(p=0.035) and Trail Making Test part B (TMT-B), and number of mistakes (p=0.043). During 
the 6-week open-label phase, significant improvements on several clinical parameters, which 
included the Positive and Negative Syndrome Scale (PANSS) total score, were observed. In 
the total population (i.e., pooled switch and continuation groups), the effect size was 0.94 
(CI 95%=0.45-1.43) as determined by the PANSS total score. 
 
Conclusions. Adjunctive mirtazapine treatment might offer added value as a neurocognitive 
enhancer, and may augment the antipsychotic effect in FGA-treated schizophrenia patients 
with inadequate treatment response. The ability to generalize these results for a larger 
population may be limited by the small sample size of the present study. 
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Introduction?
 
About 24 million people suffer from schizophrenia worldwide, yet less than 50% of this 
population receives appropriate care (World Health Organization 2001).  Even those who are 
privileged, with access to the best treatment, still suffer from severe social and functional 
deficits that are largely based on neurocognitive deficits.  Thus, developing more effective 
treatments for neurocognitive deficits is an important goal. 
 
History of schizophrenia concept  
 
Mental disorders have been described since the history of medical records began. It was the 
German psychiatrist Emil Kraepelin (1856–1926), who first classified mental illness as an 
actual disease, with a specific onset, course and outcome. As part of this classification, 
Kraepelin described the condition of ‘dementia praecox’, to identify early mental decline. 
Dementia praecox was later renamed schizophrenia, after a symptom-oriented study of this 
disorder by Swiss psychiatrist Eugen Bleuler (1857–1939) (McGlashan 2011). The term 
schizophrenia (from the Greek: schizo = split, phrenos = mind) was selected to reflect the 
poor connection between thought processes and other functions of mind such as emotional, 
behavioral, or volitional (motivational) components.  
  
 
Schizophrenic disorders 
 
Schizophrenia, schizophreniform disorder, and schizoaffective disorder are often 
conceptualized as a group of schizophrenic disorders. In addition, as with schizotypal 
personality disorder and schizoid personality disorder, schizophrenia, schizophreniform 
disorder and schizoaffective disorder all belong to the so-called schizophrenia spectrum 
disorders, as this illness typically presents a variety of symptoms with each patient, rather 
than a single psychopathology.   
 
General description and etiology 
 
Schizophrenia is a serious mental illness that is characterized by severe psychotic symptoms, 
such as auditory hallucinations. The Diagnostic and Statistical Manual of Mental and 
Behavioral Disorders 4th edition, (DSM-IV) diagnostic criteria for schizophrenia (American 
Psychiatric Association 1994) are presented in Table 1.  
 
Multiple impairments in the regulation of affect, perception, cognition and social functioning 
are common. Schizophrenia is usually associated with chronic disability and poor outcome in 
most areas of life. Due to the chronicity and pervasive functional impairments, this illness 
often requires intensive, long-term treatment.  
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Schizophrenia is a lifelong disease, where the lifetime prevalence has been estimated to be 
around 1% of the population. About 22 per 100 000 people present new cases of 
schizophrenia every year (Tsuang and Faraone 1997). This gives an incidence rate of about 
0.02%. The incidence rate is lower than the abovementioned prevalence rate, because 
schizophrenia is a predominantly chronic disorder. Thus, the presence in the population is 
cumulative. 
 
The onset of schizophrenia can range between a sudden psychosis or a gradual 
deterioration, usually between the yearly ages of 15 to 35. It has been proposed that the age 
at onset of schizophrenia is associated to its severity, where an earlier onset age has been 
associated with more severe clinical and behavioral symptoms (Lieberman et al. 1996). 
Schizophrenia affects all cultures and is equally prevalent in men and women, while the 
onset of illness is usually earlier in males (Mueser and McGurk 2004). 
 
Some questions concerning the unity of schizophrenia as a syndrome have recently 
emerged, as schizophrenia is often discussed as if it was a single disease with a common 
etiology. However, the clinical heterogeneity of schizophrenia has raised some doubts on 
this perspective, as symptoms may represent disease groups of common phenotypic 
expressions, but of diverse underlying etiopathologies (Buckley et al. 
2009). Current knowledge might also support a hypothesis for a diagnosis of schizophrenia 
according to distinct disorders, though with similar psychological or behavioral symptoms 
and clinical presentations. Several attempts to determine subtypes of schizophrenia by 
phenotype, genotype and treatment response have been made, but no sustainable results 
have been achieved thus far. There is still a discussion on whether or not to define 
schizophrenia as a neurodegenerative or neurodevelopmental disorder (Rund 2009). 
General cerebral atrophy, lateral ventricle enlargement and a lack of gliosis represent the 
variety of pathological findings in the central nervous system of patients with schizophrenia 
(Frith and Johnstone 2003; Rund 2009).  
  
While the central cause of schizophrenia is not known, many studies point towards a 
combination of genetic and environmental factors that influence brain function (Niwa et al. 
2011). Despite the research and consideration that has been invested in an effort to 
understand the etiology of schizophrenia, none of the factors seem to be especially 
significant in the genesis of schizophrenia. Instead, multiple factors seem to be involved, 
which results in multiple disorders of varied pathologies behind the schizophrenia 
phenotype. The search to uncover a specific etiology of schizophrenia has identified some of 
genetic markers that match with explanatory models, which may incorporate identified risk 
factors in the common environment. 
 
The importance of genetic factors has been demonstrated in twin studies. Concordance 
rates of monozygotic twins are approximately 41 – 65 %, and heritability estimations 
approximate 80 – 85 % of cases (Cardno et al. 1999; Cardno & Gottesman 2000). On the 
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other hand, twin studies have shown that the development of schizophrenia is not solely 
explained by genetic inheritance. In those cases where only one identical twin developed 
schizophrenia, the other identical twin developed schizophrenia in approximately 50% of 
cases. The epigenetic conclusion of this finding is that genes play an important role in 
determining whether or not an individual will develop schizophrenia, but that other factors 
must also play a significant role. Subsequent research has found that environmental factors 
have a substantial role in the etiology of schizophrenia, and contribute to approximately 30 
to 50 % of the cases (Sadock et al. 2005).  
 
Some evidence suggests that the environmental risk for schizophrenia appears to begin 
already in the first and second trimesters of pregnancy, as maternal exposure to influenza 
has been associated with an increased risk of later developing schizophrenia (Mednick et al. 
1988; Brown et al. 2004). Other environmental factors include maternal rubella, some other 
maternal viral infections, obstetric complications, low socio-economic status, maternal 
deprivation and lack of proper nutrition, natural catastrophes or war, birth in late 
winter/early spring and even urban birth (Dohrenwend et al. 1992; Lewis and Murray 1987; 
Marcelis et al. 1999; Susser et al.1996; Torrey et al.1997). Tienari et al. (2004) reported an 
increased prevalence of schizophrenia in adopted children of mothers having schizophrenia 
or schizophrenic spectrum disorder. Additional reports have process a neurodevelopmental 
hypothesis, which explains this disease as a result of multi-etiologically altered factors in 
neuronal cell birth, cell differentiation, cell migration, formation of synapses between 
neurons (synaptogenesis), programmed cell death and the malformation of neuronal 
circuitry, which later present as cognitive dysfunctions (Bunney and Bunney 1999; Eastwood 
and Harrison 2003).  
 
In summation, no single causative factor has been identified so far. The strongest evidence 
to date supports a hypothesis that identifies schizophrenia as an inherited/familial disorder, 
which is exacerbated by environmental stress. 
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Table 1 
____________________________________________________________________  
Diagnostic criteria for schizophrenia (DSM-IV, American Psychiatric Association 1994) 
 
A. Characteristic symptoms: Two or more of the following, each present for a significant portion of 
time during a 1-month period (or less if successfully treated): 
1. Delusions 
2. Hallucinations 
3. Disorganized speech 
4. Grossly disorganized or catatonic behavior 
5. Negative symptoms 
 
Only one of these five symptoms is required if delusions are bizarre, or if the hallucinations consist of 
a voice that keeps up a running commentary on the person’s behavior or thoughts, or with two or 
more voices conversing with each other. 
 
B. Social/occupational dysfunction: for a significant portion of the time, after the onset of 
symptoms, one or more major areas of functioning such as work, interpersonal 
relations, or self-care are markedly below the level achieved prior to onset (or a failure to achieve an 
expected level of achievement, when the onset occurs in childhood or adolescence). 
 
C. Duration: Continuous signs of the disturbance persist for at least 6 months, of which at least one 
month should have symptoms that meet Criterion A. This 6 months may also include periods of 
prodromal and residual symptoms. 
 
D. Schizoaffective and mood disorder exclusion: Schizoaffective disorder and mood 
disorder with psychotic features have been ruled out, due to the absence of major depressive, 
manic, or mixed episodes that have occurred concurrently with the active-phase symptoms. If such 
mood episodes have occurred during active-phase symptoms, then their total duration is brief, 
relative to the active and residual periods. 
 
E. Substance/general medical condition exclusion: The disturbance is not due to the direct 
physiological effects of a substance or another medical condition. 
 
F. Relationship to a pervasive developmental disorder: if there is a history of autistic 
disorder or another pervasive developmental disorder, the additional diagnosis of 
schizophrenia is made only if prominent delusions or hallucinations are also present for at least a 
month (or less if successfully treated). 
____________________________________________________________________ 
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Symptom domains in schizophrenia 
 
Since the concept of schizophrenia began over a century ago, the heterogeneity within this 
concept has been ontologically explained in terms of distinct clinical subtypes; i.e., 
disorganized (previously hebephrenic), catatonic, paranoid, and undifferentiated 
symptomologies. Although these subtypes are generally recognized to have poor reliability, 
low stability over time, and insignificant prognostic value, they were included in the DSM-IV. 
The fifth edition of the American Psychiatric Association's (APA) Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) was recently published, thus superseding the DSM-IV 
(American Psychiatric Association 2013).  In the DSM-5, all aforementioned subtypes of 
schizophrenia are omitted. However, the use of psychopathological dimensions in the DSM-
5 may improve its ability to describe the heterogeneity of schizophrenia (Tandon et al. 
2013). 
 
The importance of psychopathological dimensions was accepted in the field of schizophrenia 
research long before a formal discussion of diagnostic criteria began. After Kay et al. (1987) 
clustered symptoms of schizophrenia into positive, negative, and general symptoms, this 
concept became widely accepted in both scientific research and clinical work. This 
development mostly occurred after Kay et al. devised the Positive and Negative Syndrome 
Scale for Schizophrenia (PANSS) as a standardized diagnostic tool of measure, to improve the 
validity of schizophrenia research. 
  Prodromal?symptomatology?
 
Schizophrenia and its symptoms tend to gradually progress over months or years, and so-
called prodromal symptoms often precede the active phase of the disorder. Sometimes the 
symptoms emerge suddenly, which can be multiple and may include anxiety, 
purposelessness, eccentric thinking, milder forms of psychotic symptoms, and withdrawal 
from social contacts, loss of interest in previously pleasant activities, or spending most of the 
time in bed (American Psychiatric Association 1994).  
 
As the illness progresses, more pronounced problems occur with thinking, cognition, 
emotions, and behavior, which disrupts the process of making rational decisions. These 
underlying pathogenic processes produce symptoms that are variable, but typically include 
hallucinations, delusions, apathy, blunt emotional affect, odd behavior, poor personal care, 
and social withdrawal. Early prodromal signs of this illness are often identified as warning 
signs, and they can be spotted before the primary symptoms of schizophrenia occur. 
  
Because schizophrenia involves dysfunction in major areas of mentation, people in the initial 
phase of illness usually begin to have trouble in everyday life, such as problems in relations 
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or in achieving goals (Couture et al. 2006). In addition, diffuse problems with anxiety, 
depression, and suicidal thoughts or behavior are common, in addition to problems with 
substance misuse. 
  
   Positive,?disorganized,?negative,?affective?and?cognitive?symptoms?
 
Currently, the symptoms of schizophrenia are considered to fall into five broad categories; 
i.e., positive symptoms, disorganized symptoms, negative symptoms, affective symptoms 
and cognitive symptoms (Fuller et al. 2003; Tamminga and Holcomb 2005). 
 
Positive symptoms 
 
Positive symptoms include explicitly psychotic phenomena and behaviors, and people with 
positive symptoms seem to "lose touch" with reality. These symptoms can fluctuate and 
occasionally they are severe. Other times these symptoms may be hardly noticeable, 
depending on the individual and the treatment received. Positive symptoms may include 
hallucinations, delusions and formal thought disorders (Fuller et al. 2003; Tamminga and 
Holcomb 2005). 
 
Hallucinations are false auditory, visual, olfactory or tactual perceptions that have no 
relationship to reality, and which are not explained by any exterior stimuli.  Auditory 
hallucinations, often referred to as "voices", are the most common type of hallucination in 
schizophrenia (Waters et al. 2012). These voices may talk to the person about his or her 
behavior, order things to be done, or warn about dangers that otherwise do not exist. 
Sometimes there may be multiple voices, which can talk to each other. People suffering 
from schizophrenia may hear voices for a long time before others notice the significance of 
this symptom. Visual hallucinations are actually rare in schizophrenia, as are, olfactory and 
tactile hallucinations.  Regardless, the affected person cannot readily separate these 
hallucinations from real perceptions. 
 
Delusions are long-lasting false beliefs or fears that are not real and not part of the person's 
culture (Blackwood et al. 2001). Affected individuals may believe in such delusions even 
after other people (e.g., family members, friends or medical staff) have explained that such 
beliefs are not true or even logical. People suffering from schizophrenia can have delusions 
that seem bizarre, such as believing that someone else can control their thoughts, feelings or 
behavior by remote control, or that people on television are directing special messages to 
them. Sometimes one can even believe that they are somebody else, such as a famous 
historical figure. As a case vignette, a well-known Finnish patient with schizophrenia 
“Kellokosken prinsessa” (Anna Lappalainen, 1896–1988) thought that she was a real 
princess, although she had no known connection to royalty (Raitasuo and Siltala 2010). 
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Persons with such delusions may have paranoid beliefs that someone is trying to harm them; 
e.g., by cheating, harassing, poisoning, spying, or plotting against them or people they care 
about. Such beliefs are referred to as delusions of persecution. Delusions can sometimes 
cause serious harm or even danger to others, as the affected person may try to defend 
him/herself against the imaginary threat. 
  
 
 Disorganized?symptoms?
 
Thought disorders are uncommon, dysfunctional and usually illogical ways of thinking (Fuller 
et al. 2003). One may, for example, have difficulties in organizing thoughts or logically 
connecting them to emotions. This sort of disturbance is called "disorganized thinking", 
which is one form of thought disorder. One may talk in a muddled way that is hard to 
comprehend, and illogical reasons may substitute for rational explanations. One may, for 
example, stop speaking unexpectedly in the middle of an idea. When asked why the 
explanation has stopping, the affected person may say that the thought had been taken 
away, or that the thought is hiding in “the mountains of the brain”. Perhaps the most 
disturbed type of formal thought disorder may result in meaningless words or neologisms. 
Neologisms are newly created words, terms or phrases, which are used independently of 
their common meaning; i.e., the words only have meaning to the person who uses them. 
The basic idea of thought disorders is that concepts from different contexts are mingled 
together in a way that is against normative logic.  
 
Some individuals with schizophrenia also have movement disorders, such as agitated body 
movements (Walther and Strik 2012). A person with a movement disorder may compulsively 
repeat certain motions while some may become catatonic. This may include motor 
hyperactivity, odd body and limb positions or even a state of neurogenic motor immobility 
(stupor). Non-medicated catatonia is nowadays infrequent, but it was more common before 
modern psychopharmacological treatments for schizophrenia. 
  
 Negative?symptoms?
 
The negative symptoms of schizophrenia include problems with motivation, social 
withdrawal, diminished affective responsiveness, speech, and movement (Fuller et al. 2003; 
Tamminga and Holcomb 2005). "Flat affect", meaning a lack of common emotional gestures, 
or monotonous talk with a face that does not move, is a common example of this category. 
Negative symptoms may be harder to recognize, and they can be mistaken for depression or 
amotivational conditions like unwillingness or laziness. Research suggests that negative 
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symptoms influence poor functional outcomes and quality of life for individuals with 
schizophrenia than do positive symptoms (Velligan et al. 1997; Norman et al. 2000; Lysaker 
et al. 2004; Lysaker and Davis 2005; Milev et al. 2005; Kirckpatrick et al. 2006). Negative 
symptoms tend to live on longer than positive symptoms, and are usually more difficult to 
treat (Kirkpatrick et al. 2006; Alphs 2006). Moreover, negative symptoms are associated with 
impaired functional outcomes such as diminished independent living skills or reduced social 
functioning (Leeuwenkamp et al. 2007). 
  
  Affective?symptoms?
 
In addition to the previously described positive, disorganized or negative symptoms, patients 
with schizophrenia often exhibit affective symptoms, such as depression and anxiety. 
Affective symptoms are common in schizophrenia and can be particularly disturbing, even to 
the point of increasing the risk of suicide (Hor and Taylor 2010) and diminishing both the 
quality of life and life span of these individuals. For this reason it is important that affective 
symptoms are properly diagnosed and treated accordingly. The majority of patients with 
schizophrenia who commit suicide do so while experiencing depressive symptoms (Hawton 
et al. 2005). Depressive symptoms are reported in up to 80% of the patients with 
schizophrenia, while symptoms of mania are reported in about 20% of these cases (Kasckow 
et al. 2010). Moreover, only part of the patients with schizophrenia meet the established 
criteria for major depression, while even more experience subclinical depressive symptoms 
(Kasckow et al. 2010). Schizoaffective disorder is another condition, where the individual 
experiences a combination of schizophrenic symptoms and affective symptoms, such as 
mania or depression. 
  
 Neurocognitive?symptoms?
 
In addition to positive symptoms (delusions and hallucinations), negative symptoms (like 
reduced poverty of speech and blunted affect), and affective symptoms (depression, mania 
and anxiety), schizophrenia is also associated with changes in cognitive symptoms. Cognitive 
symptoms typically include problems with attention (shorter), memory (diminished) and 
declined executive functioning (i.e, the ability to understand information and use it to make 
decisions). Declinations in cognitive symptoms typically reflect dysfunctions in the central 
nervous system. These are often referred to as neurocognitive functions, and are distinct 
from the mental processes of formulating inner meanings or inspecting connections 
between thoughts, emotions and behavior. Therefore, the term neurocognitive symptoms is 
used in this research to describe brain dysfunctions that are related to the cognitive process.  
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The presence of neurocognitive symptoms is independent of positive symptoms, but 
cognitive symptoms are associated with both disorganized symptoms and negative 
symptoms (O'Leary et al. 2000). It has been argued that neurocognitive deficits may present 
as a trait-like component of schizophrenia by comparing it to a neurodevelopmental disease 
(Kristensen and Myatt 2011). Although neurocognitive symptoms are currently recognized as 
a core feature of schizophrenia, they are commonly understated in clinical settings. In 
contrast to negative symptoms, neurocognitive symptoms are often difficult to recognize 
and they are mostly identified after psychological testing.  
  
  
Neurocognitive impairment and dysfunctions in schizophrenia 
?
Although neurocognitive deficits are a trait-like component of schizophrenia, there is 
currently no specific neurocognitive profile for schizophrenia (Mohamed et al. 1999; Bilder 
et al. 2000). While no particular type of neurocognitive deficit is unique to schizophrenia, 
tasks that require active retrieval of verbal material from long-term memory, visuo-motor 
processing, attention, vigilance or integrity of executive functions seem to be difficult for 
most of these patients (Blanchard and Neale 1994; Heinrichs and Zakzanis 1998; Nopoulos et 
al. 1994; Raine et al. 1992; Saykin et al. 1994; Sullivan et al. 1994).  The neurocognitive 
performance of patients with schizophrenia is generally one to two standard deviations 
below the scores of healthy controls. Compared with other severe mental disorders, like 
major depression or bipolar disorder, patients with schizophrenia present a wider range of 
neurocognitive domains and to a more severe degree (Buchanan et al. 2005).   
 
 Neurocognition?in?psychotic?illness?
 
While there is no single causative etiology for the neurocognitive deficits in schizophrenia, a 
current hypothesis considers schizophrenia to be a neuropsychiatric disorder with 
neurocognitive deficits as a major trait component (Keefe and Fenton 2007). Moreover, 
neurocognitive problems can lead to an increased risk for both illness and a more severe 
symptomatology.  
 
A stress vulnerability model was originally proposed by Zubin and Spring (1977). This   
approach suggests that an individual has biological, psychological and environmental (or 
social) components, which all contain strengths and vulnerabilities for coping with stressors. 
Vulnerability in this context is a variable that results in a failure to cope with stress, which 
may then cause an increased risk for information processing problems, and this becomes 
part of a process that leads to psychotic symptoms. In conjunction with vulnerability factors, 
environmental factors can influence both the onset and course of such symptoms. Living in a 
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stressful environment, with seemingly insurmountable conflicts or criticism, may contribute 
to more stress than the individual can successfully cope with. Also, the misuse of drugs such 
as amphetamine or sometimes even cannabis may contribute  to the development of 
psychotic symptoms in vulnerable individuals. According to the stress-vulnerability model 
(Zubin and Spring 1977), symptoms or psychoses emerge when stress exceeds an individual’s 
vulnerability threshold. The model is obviously simplistic and it has since been revised in 
more sophisticated models, such as that of Nuechterlein and Dawson (1984). 
 
According to the stress-vulnerability model (and thus accepting the predisposed biological 
vulnerability factors), schizophrenia is widely accepted as a brain disease with affections on 
brain function and even brain structure (Harrison 1999). Numerous studies have tried to find 
biological markers for this vulnerability in (mainly first-degree) relatives of patients with 
schizophrenia. Prefrontal cortex dysfunctions (Allen et al. 2011) have been consistently 
reported in schizophrenia studies, and this phenomenon has frequently been identified as 
one of the major causes of the executive function deficits seen in schizophrenia (Minzenberg 
et al. 2009). Among prefrontal cortex dysfunctions, general cortical thickness and 
degradation (Kuperberg et al. 2003; Harris et al. 2004; Puri 2010), ventricular enlargement 
(Gaser et al. 2004), reduction in brain volume and weight (Lawrie and Abukmeil 1998; 
Harrison et al. 2003), abnormalities in gray and white matter (Cannon et al. 2002; Job et al. 
2002; Puri 2010), altered hippocampal shape and volume (Suddath et al. 1989; Gur et al. 
2000; Wiegand et al. 2004) have all been observed in both never medicated first-episode 
patients and patients with longer durations of illness.  
 
With functional magnetic resonance imaging, abnormal brain activity and a lack of neuronal 
connectivity have been identified in the mechanisms of distributed circuits that involve the 
prefrontal cortex of patients with schizophrenia (Ragland et al. 2004). This is in addition to 
significantly reduced activation, predominantly in the right hemisphere, also in the 
dorsolateral frontal and temporal regions, and in the inferior parietal areas and sub-
cortically in the thalamus (Shenton et al. 2002; Salgado-Pineda et al. 2004, Ragland et al. 
2007; Tseng et al. 2009).  
 
It seems clear that disturbed neurocognition and brain dysfunctions are a major part of 
schizophrenia. Moreover, acute psychosis itself can be somehow seen as a decompensation 
mechanism of general information processing. In stressful situations, for example, an 
underlying vulnerability affects the individual’s capacity to consider the world in a rational or 
normological way, which is identified by impaired reality testing.  
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Schizophrenia?is???neurocognitive?psychosis?
 
Neurocognitive impairment is regarded as a core component of schizophrenia, and is 
increasingly under investigation as a potential target for treatment modalities. On average, 
cognitive impairment in schizophrenia is severe to moderately severe when compared to 
healthy controls, and almost all patients demonstrate neurocognitive impairments. Similarly, 
when comparing patients with severe affective disorders (i.e., major depression or mania), 
cognitive impairment in schizophrenia emerges earlier, is more severe, and tends to be 
independent of clinical symptoms. To this effect, a growing body of evidence suggests that 
the neurocognitive deficits observed in patients with schizophrenia are both primary and a 
core domain of the illness. Thus, schizophrenia is a neuropsychiatric disorder with 
neurocognitive deficits as a major component (Keefe and Fenton 2007).  
 
  
 
 
Neurocognition and Neuropsychology 
 Neuropsychology?and?neuropsychological?examination?
 
Neuropsychology is a scientific explanation of psychology, which combines different aspects 
of brain structure and function, in relation to their putative behavioral and psychological 
processes. This approach combines clinical and experimental methods of psychology that 
aim to study, assess, explain and treat such processes as thinking, feeling and behavior as 
they directly relate to brain function. Neuropsychology shares the same view of mental 
information processing as cognitive psychology, and the same terms are used in both fields 
of study.  
 
In clinical settings, when examining patients with schizophrenia, neuropsychology employs 
psychological, neurological and physiological methods to evaluate neurocognitive processes. 
This includes cognitive, emotional and behavioral domains, and relates relevant findings of 
the examination to normal and abnormal functions of the central nervous system.  
 
The main method in neuropsychology is neuropsychological testing. The tasks of different 
tests have been designed to link the performance on the task with one or more 
neurocognitive processes. These tests are typically standardized, meaning that they have 
been administered in general population to obtain normative values.   
 
Typical examples of neuropsychological tests include the Wechsler Adult Intelligence Scale 
(WAIS, Wechsler 1981; Lezak 1995), the Wechsler Adult Memory Scale (WMS, Wechsler 
1945), the Wisconsin Card Sorting Test (WCST, Monchi et al. 2001), the Stroop Colored Word 
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Test (Jensen and Rohwer 1966; Reitan and Wolfson 1985; Lezak 1995) and the Trail Making 
Test (TMT, Reitan and Wolfson 1985; Lezak 1995).  
  
 
 
Major Neurocognitive functions and their schizophrenia related deficits  
 
There are various important aspects to evaluate in human neurocognition and its 
impairment. The precise terms may vary, depending on the specific approach, and no 
rigorous taxonomy exists. However, attention, verbal (or language) skills, visual (or 
perceptional) skills, motor skills, memory, and executive functions are commonly accepted 
as the main terms that are used to describe the major neurocognitive domains. Also, the 
concept of measurable intelligence must be mentioned as an important dimension of 
cognition. However, the concept of intelligence encompasses a general collection of 
cognitive functions, abilities and cultural values, so the best choice is to examine patterns of 
deficits in specific domains, even though a global decline in intellect is a common feature in 
schizophrenia (Blanchard and Neale 1994; Bilder et al. 2000).  
 
While there is some localization in different neurocognitive functions of the brain, these 
cannot be completely localized to any specific brain area. In other words, different areas in 
the brain are more specialized for some neurocognitive processes than others, and the 
central nervous system also integrates and connects the information produced in these 
regions. 
  
 Attention?
 
Attention is a multifactorial construct, which includes the ability to maintain an alert state 
(for a specific amount of time), to orient to new stimuli, to filter information and to 
distinguish stimuli over some duration of time. Attention is a cognitive process of selectively 
concentrating on some feature(s) in the environment while ignoring others. Thus, attention 
refers to processes where the individual becomes alert to internal or external stimuli (Lezak 
et al. 2004). The critical elements of attention are focusing, selectivity, exclusiveness, and 
vigilance (Lezak et al. 2004). To choose from a flow of stimuli and sustain attention are the 
fundamental requirements for all cognitive functioning. A close relationship between 
attention, working memory and vigilance is close and in they are somehow part of the same 
process. A neural correlate of attention is the enhanced firing of neurons.  It has been shown 
that receptive fields and thus response properties of sensory-cortical neurons are stimulus-
specifically modulated during selective attention to filter task-relevant stimulus features 
from amongst irrelevant ones (see Jääskeläinen et al. 2011) 
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While individuals who suffer from schizophrenia demonstrate a wide variety of attention 
deficits, these deficits seem to be independent of both the clinical state and medication, and 
are present at the earliest stages of the disease (Saykin et al. 1991; Cornblatt and Keilp 1994; 
Heinrichs and Zakzanis 1998; Cornblatt et al. 1997; Albus et al. 2006). 
  
 Verbal?skills?
 
Verbal skills are a part of general verbal intelligence, which means the ability to analyze 
information and solve problems using language-based reasoning. Verbal skills include the 
ability to listen and recall spoken information, understand the meaning of spoken or written 
information, solve language-based problems, understand the relationships between 
language concepts and perform language comparisons or analogies, and to perform 
multipart language-based analyses. In society, verbal reasoning is important to most aspects 
of everyday life, such as attending school or working.  
 
When testing patients in research on schizophrenia, basic verbal reasoning is typically 
evaluated through brief tests. According to a large meta-analysis by Heinrichs and Zakzanis 
(1998), basic verbal skill impairments were apparent with standard deviations between 0.5 
and 0.8, depending on tasks. 
  
 
 Visual?processing???
 
Visual processing, visual perception and visuo-construction are the basic processes of the 
brain’s visual system. Visual processing is the sequence of events that allows information to 
flow from visual sensors in the retina to cognitive processing in the brain. Visual perception 
is the ability to precieve the immediate environment by processing information that has 
entered the eye as visible light. The resulting perception is also known as eyesight, sight, or 
vision (adjectival form: ocular, optical, visual, respectively). Visuo-construction is a skill that 
involves the ability to organize and reconstruct spatial information to make a design. 
Sometimes it is defined as one of the general intelligence factors (Carrol 1986). 
 
Heinrichs and Zakzanis (1998) reported that individuals with schizophrenia score between 
0.5 to almost 1.5 standard deviations below the control mean in various visual /spatial ability 
tests. However, compared with other domains of neurocognition, visual/spatial problems 
seem to be somewhat smaller. The problematic part of this evaluation is the fact that 
executive functions are to some extent part of visual processing, especially when 
constructing designs from observed stimuli or when choosing strategies for either visuo-
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constructive or spatial processes. Executive functions are part of the total process in these 
cases, and its execution is often significantly disturbed in schizophrenia.  
  
 Motor?skills?
 
Motor dysfunction is a consistent finding in retrospective high-risk and archive-using studies 
of schizophrenia (Jones et al. 1994; Jones and Done 1997; Walker et al. 1999; Mittal et al. 
2010). Delayed motor development, and at least mild motor dysfunctions that persist 
throughout infancy, have been observed in those individuals who later developed 
schizophrenia, and in their unaffected adult first-degree relatives (Kinney et al. 1986; Fish et 
al. 1992; Cantor-Graae et al. 1994; Ismail et al. 1998).  It is a constant and obvious finding 
that movement abnormalities and motor dysfunctions are related to the emergence of 
schizophrenia, and longitudinal studies indicate that these features precede the onset of 
clinical symptoms (Walker 1994; Rosso et al. 2000). In addition to congenital motor 
dysfunctions, medication, and especially the first-generation antipsychotics (FGAs) may 
generate problems with motor functioning.  
 
  
 Memory?
 
Memory is a complex system that allows an individual to register, encode, store, retain, and 
eventually retrieve information (Lezak et al. 2004). The first phase in memory is registering 
the stimuli, which is followed by editing the information for storage in the memory. As a 
result of this encoding, external information is processed physically and chemically in 
sensorial systems. The second phase in processing a memory is the storage of encoded 
information. This property makes it possible to retain information over time. Retrieval, in the 
final phase, allows us to use the retained information. Initially, when trying to remember 
something, we must locate stored information and return it to our consciousness.  Memory 
and learning are close concepts, and memory can be considered as a result of learning.  
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The memory system is often divided into short-term and long-term memories. Short-term 
memory can be divided into immediate and working memory, while long-term memory 
includes declarative (explicit) memory and non-declarative (implicit) memory (Figure 1). 
 
 
 
 
 
 
Figure 1. Human memory system. 
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Memory cannot be localized to any specific area of the brain, and is the result of co-work 
between multiple neural networks. However, some parts of the brain may have more 
significance for remembering when compared with others. Different brain areas are 
activated in different types of memory (Figure 2).  
  
 
Figure 2 
    
 
A. Sensory memory systems, are located mostly in parietal and occipital cortex (colored light gray). 
Working memory (associated with executive functions) are processed mainly in frontal lobe  
(colored dark grey). 
B. Inner occipital lobe, hippocampus (1) and thalamus (2) process events and things before storage 
it in cortical systems. Basal ganglia (3) comprise a group of structures that are involved remembering  
movements and skill learning. The amygdala (4) is involved in fear-learning (in addition to complex  
processing of emotions). 
 
 
It has been known at least since the 1990s that there are consistent and comprehensive 
memory impairments in schizophrenia (Aleman et al. 1999). Verbal memory, including story 
recall and word list learning, seems to be more severely affected than non-verbal memory 
(Saykin et al.1991). Memory impairments are detected in both episodic and semantic forms 
of memory (Saykin et al. 1991; Saykin et al. 1994; Heinrichs and Zakzanis 1998; Cirillo and 
Seidman 2003). In their meta-analysis, Cirillo and Seidman (2003) proposed that verbal 
declarative memory is among the most defected neuropsychological functions in patients 
with schizophrenia. While the recognitive memory of patients with schizophrenia tends to 
be more or less intact (Conklin et al. 2002), the major problems are found in learning and 
1 2 
3 
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especially the use of effective learning strategies, which means more impairment in explicit 
than implicit memory systems (Sponheim et al. 2004). However, impaired recognition is 
sometimes detected, at least in the patients who have a severe decline in memory function 
(Clare et al. 1993; Landrø 1994), which may indicate that consolidation process of 
information could also be impaired. 
  Executive?functions?
  
The executive functions comprise the capacities for volitional activity, forward planning and 
self-regulation (Lezak et al. 2004). Executive functions control and manage other cognitive 
processes and are often described as a central executive unit of the brain and the whole 
cognitive system. Executive functions are a part of the process an individual uses to achieve 
purposeful behavior (Lezak et al. 2004). Executive functions include the ability to evaluate 
situations, choose and formulate strategies and solve problems, which provide the ability to 
adaptively shift to new situations or strategies. Some definitions of executive functions 
include even more dimensions. For example, according to Chan et al. (2008), executive 
functions are an umbrella term for neurocognitive processes such as planning, working 
memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, multi-
tasking, and both the initiation and monitoring of actions. These functions are largely carried 
out by brain prefrontal areas, and sometimes executive functions are even called frontal 
functions. However, other areas of brain (for example the parietal lobe) are also involved in 
executive functions, and there is no exclusive relationship between executive functions and 
frontal lobe activity. Patients suffering schizophrenia have impairments in many areas of 
executive functioning, and the degree of decline is usually severe in schizophrenia (Heinrichs 
and Zakzanis 1998).  
  
 Summary?of?neurocognitive?dysfunctions?associated?with?schizophrenia??
 
The neurocognitive deficits in schizophrenia are especially pronounced in many domains of 
information processing. While no particular type of neurocognitive deficit is unique to 
schizophrenia, tasks that require active retrieval of verbal material from long-term memory, 
visual-motor processing, attention, vigilance or integrity of executive functions seem to be 
significantly difficult for most patients with schizophrenia (Blanchard and Neale 1994; 
Heinrichs and Zakzanis 1998; Nopoulos et al. 1994; Raine et al. 1992; Saykin et al. 1994; 
Sullivan et al.1994). It is now thought that impaired neurocognitive deficits may be a core 
finding in schizophrenia. 
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The nature of the neurocognitive deficits in schizophrenia 
 
Neurocognitive impairment in schizophrenia is diffuse and pervasive, with performance 
deficits of approximately 1 to 2 standard deviations below non-psychiatric control samples 
across most cognitive domains; i.e., memory, attention, processing speed, vigilance, and 
executive functions (Gold 2004; Green 2006; Heinrichs and Zakzanis 1998). Although there 
are reports of individuals with schizophrenia demonstrating neurocognitive performance 
within the normal range, these high-functioning individuals do appear to show impairments 
relative to their estimated premorbid abilities (Reichenberg et al. 2005), and particularly for 
speeded tasks and working memory tests (Wilk et al. 2005). 
  
?
Course of the neurocognitive deficits in schizophrenia 
 
Two contrasting hypotheses have been argued on the course of neurocognitive deficits in 
schizophrenia. Some studies have suggested that cognitive function deteriorates over time, 
whereas others have reported stability or even an improvement in some functions (Delisi et 
al. 1995; Rund 1998).  This question on the longitudinal course of schizophrenia is important 
in considering schizophrenia as a neurodegenerative (progressive) disorder or as a stable 
disease that result from a developmental defect. Moreover, neurocognitive deficits have 
become potential biological markers, or endophenotypes, that might ease in the 
identification of genetic factors that are involved in vulnerability to schizophrenia. To serve 
as reliable endophenotypes for schizophrenia, neurocognitive factors should be stable over 
time, and the non-genetic factors affecting its severity could be identified and used to obtain 
standardized values. There is also an increasing interest to improve neurocognitive functions 
in patients with schizophrenia through pharmacological treatments or cognitive remediation 
programs.  
 
Recent evidence has suggested that neurocognitive deficits are independent of both clinical 
state and medication, and they are present at the initial episode of the disease (Saykin et al. 
1994; Heinrichs and Zakzanis 1998; Albus et al. 2006). In patients with schizophrenia, 
neurocognitive deficits are present even before the first psychotic episode (Caspi et al. 
2003). In fact, evidence points towards existing cognitive deficits already in childhood, 
before any psychotic illness (Osler et al. 2007; Maccabe 2008). Most studies point to a  
course of neurocognitive deficits being relatively stable without any significant worsening 
(Maccabe 2008; Frangou et al. 2008; Szöke et al. 2008). However, in addition to these facts, 
which supporting the idea of neurocognitive deficits as a sign of neurodevelopmental 
vulnerability factors, there are also findings that show neurocognitive deterioration at the 
time of the first psychotic episode (Lieberman et al. 1996). Furthermore, most experienced 
clinicians can readily identify a deteriorating course of neurocognition in their patients over 
time. Controversial results may be due to different subgroups of patients with 
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neurocognitive deficits, and different courses of illness in these subgroups.  Over all, people 
with schizophrenia have been shown to have a wide range of cognitive deficits, but at least 
part of the longitudinal course of these deficits remains unclear, and further longitudinal 
studies are still needed to clarify this issue.  
   
When designing studies to examine the possible enhancing effects of pharmacological 
agents, practice effects should be taken into account. The observable neurocognitive 
improvements in the patients with schizophrenia may result from real improvements in 
neurocognition, a practice (learning) effect, or a combination of the two. However, the 
practice effect alone might explain a perceptible improvement in neurocognition when tests 
are repeated several times, and this might also mask a concurrent worsening in some 
neurocognitive processes. This means that the practice effect may either simulate 
neurocognitive improvement, or attenuate the real-life impairment. To avoid these 
distortional effects of cognitive measurements, and to ensure that results can be correctly 
interpreted, the practice effect should be taken into account in the design of neurocognitive 
studies. For this reason, the use of a control group is of principal importance. It may also be 
important to match the groups, not only in terms of basic demographic characteristics (e.g., 
age, gender, education etc.), but also for familiarity with the tests and, more generally, for 
familiarity with testing circumstances in general. 
  
 
 
Neurocognitive impairment as a determinant of outcome 
 
In general, neurocognitive deficits in schizophrenia are related to poor global functioning 
(Velligan et al. 2000), and in particular to impaired community functioning, decreased 
instrumental and problem-solving skills, poor success in psychosocial rehabilitation 
programs (Green et al. 2000), and failure in long-term employment (Bryson and Bell 2003).   
 
It has been progressively recognized that the severity of neurocognitive impairment is a 
major determinant to outcome in schizophrenia. It has been reported that neurocognitive 
deficits can account for up to 20 - 60% of the functional outcome in patients with 
schizophrenia (Green et al. 2000; Keefe and Fenton 2007; Keefe et al. 2007; Weinberger and 
Gallhofer 1997). This relationship is even more pronounced in chronic, highly symptomatic 
patients (Verdoux et al. 2002). Despite the use of different pharmacological treatments and 
psychosocial strategies, most patients with schizophrenia are still suffering from 
neurocognitive impairments that severely limit their social and vocational functioning. 
Therefore, interventions to improve neurocognitive function also have the capacity to 
improve quality of life. Thus, development of social and occupational outcomes remains one 
of the primary goals in the treatment of schizophrenia (Hyman and Fenton 2003).  
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Pathophysiological background of neurocognitive impairment in schizophrenia 
 
As discussed previously, both the etiology and validity of schizophrenia, as single etiological 
category of mental disorders, is debatable (Dutta et al. 2007; Tandon et al. 2008). Lacking of 
a substantial knowledge of the etiology, entity and neurobiology of schizophrenia means 
that it is also difficult to characterize the specific neurobiological abnormalities underlying 
the disease, and the neurocognitive impairments associated with it.  
 
The classic hyper-dopaminergic model (Carlsson and Lindquist 1963; van Rossum 1966), 
postulated that psychotic symptoms in schizophrenia were the result of too much dopamine 
transmission. Subsequent studies with functional neuroimaging suggest that negative 
symptoms, as well as neurocognitive dysfunctions in schizophrenia, may be partly due to a 
dysfunction in dopamine neurotransmission at D1 dopamine receptors in the medial 
prefrontal cortex (Goldman-Rakic et al. 2004; Castner et al. 2004). An integrative approach 
originally based on single-photon emission computed tomography- and positron emission 
tomography-based studies postulated that schizophrenia is characterized by an imbalance 
between subcortical and cortical dopamine systems (Knable and Weinberger, 1997). . 
According to this idea, subcortical mesolimbic dopamine projections may be hyperactive, 
thus resulting in hyper-stimulation of D2 receptors (and positive symptoms), while 
mesocortical projections to the prefrontal cortex (PFC) may be hypoactive, thus resulting in a 
concurrent hypostimulation of D1 receptors, which could lead to neurocognitive deficits or 
negative symptoms (Knable and Weinberger 1997). There are also etiological theories that 
have focused attention on a possible alteration in the glutamate neurotransmitter system, 
especially involving N-Methyl-D-aspartic acid (NMDA) receptor function (Javitt and Zukin 
1991; Olney and Farber 1995) or impaired gamma-aminobutyric acid (GABA) 
neurotransmission (Benes and Berretta 2001; Lewis and Hashimoto 2007).  Some studies 
have suggested that neurocognitive deficits in schizophrenia may be related to alterations in 
GABA neurotransmission (Costa et al. 2001; Brigman et al. 2006). Some recent studies 
suggest that alterations in glutamate receptor function may contribute to the development 
of the GABAergic pathology associated with schizophrenia (Keshavan et al. 2011). 
 
Dysfunctions in glutamatergic and GABAergic systems may lead to severe imbalances 
between the excitatory and inhibitory systems of the brain, possibly forming a fundamental 
deficit for schizophrenia, while monoaminergic (including 5-HT, dopamine and other 
monoamines) dysfunction could be a secondary result of this imbalance (Miyamoto et al. 
2012).   
 
While neurocognitive dysfunction probably reflects the core pathological processes in 
schizophrenia, a comprehensive theory to integrate the complex pattern of positive 
symptoms, negative symptoms, neurocognitive decline and neurobiology in schizophrenia 
remains obscure. Despite the paucity of neurobiological data for this disease, any 
dysfunction in the major neurotransmitter systems (e.g., dopaminergic, glutamatergic, 
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cholinergic, serotonergic and GABAergic) is of importance to the functional neurobiology of 
schizophrenia (Galletly 2009).  
  
When trying to understand the neurobiology of schizophrenia, and the neurocognitive 
impairment in schizophrenia, the challenge remains to integrate a growing body of evidence 
that relates neurotransmitter systems with genetic and other risk factors. Such efforts 
stimulate the development of hypotheses that account for these findings, in order to 
discover new treatments for neurocognitive dysfunction (Galletly 2009). 
  
 
Strategies to enhance neurocognition in schizophrenia  
 
Established treatment guidelines for schizophrenia (American Psychiatric Association 2004 
and 2009; National Institute for Health and Care Excellence (NICE) 2009, Galletly 2009, 
Barnes et al. 2011) generally consider dopamine antagonists (antipsychotics) as the most 
effective way to diminish active positive symptoms of schizophrenia. It has been 
recommended that antipsychotic medications should be administered at the earliest stages 
of schizophrenia, thus forming a critical part of early intervention amenities. This approach is 
also based on the presumption that early treatment- will minimize possible negative 
consequences of active neuronal morbidity, and subsequently improve both symptomatic, 
neurocognitive and functional outcomes (Marshall et al. 2005; Perkins et al. 2005; Galletly 
2009). It has also been hypothesized that antipsychotic treatment at the first episode of 
schizophrenic psychosis can prevent the progression of structural brain changes (Li and Xu 
2007; Lieberman et al. 2005 and 2008).   
 
There are two central approaches to enhance neurocognitive performance in patients with 
schizophrenia: non-pharmacological (for example neuropsychological rehabilitation) and 
pharmacological. Most of these patients are treated pharmacologically. Over 60 years have 
passed since the synthesis of chlorpromazine, on 11 December of 1950, and dopamine 
receptor D2 blockade is still an important objective in the psychopharmacological treatment 
of schizophrenia.  However, these antipsychotic drugs have only a limited efficacy on the 
negative and neurocognitive symptoms of schizophrenia. The inadequate response to 
treatment is more apparent in subgroups of symptoms. In particular, while antipsychotic 
drugs are often effective at controlling the positive psychotic symptoms, they are less able to 
ameliorate the negative and cognitive symptoms of schizophrenia. These include social 
withdrawal, blunted mood, lack of self-care and deficits in both executive function and 
working memory. When combined with depressed mood, this spectrum of symptoms is 
more problematic for integrating the patient into society. As no single antipsychotic agent 
has been consistently shown to be a neurocognitive enhancer, various adjunctive 
psychopharmacological agents have been studied, yet so far with inconsistent and evasive 
results (Keefe et al. 2007; Galletly 2009).  
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Some of the possible neuro-enhancing adjunctive agents that have been studied are 
antidepressants. Within this class of drugs, mirtazapine has demonstrated a unique, wide-
range mechanism of action that includes antagonism of the noradrenaline alpha-2 receptor, 
serotonin 5-HT2 and 5-HT3 receptors, and indirect agonism of the 5-HT1A receptor (Anttila 
and Leinonen 2001). All of these monoaminergic receptors seem to be involved in the 
modulation of neurocognition (Akhondzadeh et al. 2009; Galletly 2009; Sumiyoshi et al. 
2007). The pro-neurocognitive effect of adjunctive mirtazapine was first reported in an open 
label study by Delle Chiaie et al. (2007), which has subsequently been replicated in a limited 
randomized controlled trial (RCT) (Cho et al. 2011). 
 
  
 
 
The effects of antipsychotic drugs on neurocognition 
 
FGAs emerged in the early 1950s, when the efficacy of chlorpromazine was first described in 
the treatment of psychotic symptoms (Delay et al. 1952). FGAs are still in wide use, although 
are other types of antipsychotics are currently available. The desired effect of FGAs on the 
positive psychotic symptoms has been shown to result from their ability to inhibit dopamine 
D2 receptors in the brain (Carlsson and Lindqvist 1963; Lieberman et al. 2005; Leucht et al. 
2009).  Unlike the other FGAs, chlorpromazine has high affinity for D1 receptors. 
 
The endeavour to develop effective antipsychotics with a better tolerability profile, and with 
a more comprehensive profile of effects, led to the advent of SGAs, which are also known as 
atypical antipsychotics. Clozapine, the prototypical SGA, has demonstrated a higher efficacy 
in treatment-refractory schizophrenia and a lower incidence of extrapyramidal symptoms 
(EPS) than FGAs. These unique features are referred to as atypical. These advantages from 
clozapine are probably attributed to its high affinity to serotonin 5HT2 receptors and 
relatively low affinity to dopamine D2 receptors, as opposed to FGAs, which generally have 
high affinity for D2 and relatively less interaction with 5HT receptors (Meltzer 1994). Based 
on this concept of serotonin dopamine antagonism, a number of novel SGAs have been 
developed to replace clozapine, due to its serious adverse effects. 
 
Much optimism accompanied the early reports that favored SGAs over FGAs in the vast 
majority of clinical domains. However, the supremacy of SGAs has recently been questioned, 
as large independent studies have failed to show that most SGAs are safer or more effective 
than most FGAs (Jones et al. 2006; Tiihonen et al. 2006). Nevertheless, evidence exists in 
favor of SGAs in terms of negative symptoms of schizophrenia (Davis et al. 2003), chronic 
schizophrenia with a history of suboptimal response to treatment (Volavka et al. 2002), 
adverse effect profile (Dossenbach et al. 2004), treatment adherence (Kahn et al. 2008) and 
discontinuation of treatment (Lieberman et al. 2005). 
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Various interventions to improve neurocognition in schizophrenia have provided equivocal 
results (Galletly 2009; Keefe et al. 2007). In the 1990s, the first reports on SGAs as probable 
neurocognitive enhancers led to an enthusiasm that has eventually turned into a growing 
uncertainty.  In contrast, it seems that FGAs may be either neutral or even able to recover 
rather than impair neurocognition (Keefe et al. 2006).  In the Clinical Antipsychotic Trials of 
Intervention Effectiveness study (CATIE) (Keefe et al. 2007) FGAs have even slightly 
outperformed some SGAs in some cases. 
 
Aside from the FGAs vs. SGAs controversy, the modest and disappointing neurocognitive 
effects of all antipsychotics has brought the basic research back to evaluate pharmacological 
adjuncts with possible neurocognition-enhancing properties. As a result, antidepressants 
with monoamine receptor-mediated mechanisms of action such as mianserine or 
mirtazapine, have become a promising candidate group (Poyurovsky et al. 2003). This is in 
contrast to the vast majority of both old and new antidepressants, e.g., SSRIs, that inhibit 
the action of monoamine transporters, which are technically not receptors. 
 
??
Mirtazapine as a plausible neurocognitive enhancer 
 
The neurocognitive effects from add-on antidepressants in schizophrenia have been studied 
in only a small number of RCTs, and with contradictory results. For instance, the serotonin 
reuptake inhibitor citalopram did not yield any benefits (Friedman et al. 2005), while 
adjunctive mianserine, a serotonin receptor-blocking antidepressant with a mechanism of 
action fairly close to mirtazapine, did improve neurocognition in FGA-treated schizophrenia 
patients (Poyurovsky et al. 2003). One explanation for this beneficial effect of mianserin 
might be due to its inhibition of serotonin 5-HT2 receptors – a feature that FGAs [in contrast 
to SGAs] are lacking. 
 
Mirtazapine is an antidepressant with a distinct mechanism of action that includes 
antagonism of presynaptic noradrenaline a2, serotonin 5-HT2 and 5-HT3 
receptors, and indirect agonism of the 5-HT1A receptor (Anttila  and Leinonen 2001), which 
have all been shown to enhance neurocognition (Akhondzadeh et al. 2009; Galletly 2009; 
Sumiyoshi et al. 2007). Adjunctive mirtazapine has been frequently promoted to improve 
negative symptoms of schizophrenia (Berk et al. 2001; Joffe et al. 2009; Zoccali et al. 2004), 
and even positive symptoms in FGA-treated schizophrenia patients (Joffe et al. 2009).  
However, it is currently unknown whether or not adjunctive mirtazapine would also have a 
beneficial effect on neurocognitive processes.  
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Aims?of?the?study?
 
 
1. To explore the effect of 6-week adjunctive mirtazapine treatment on neurocognitive 
symptoms of schizophrenia in patients with no response, or only a sub-optimal 
response, to different FGAs in stable dosages. 
 
 
2. To evaluate predictors and mediators of a possible enhancing effect from adjunctive 
6-week mirtazapine treatment on neurocognition in patients with schizophrenia with 
no or only a sub-optimal response to different FGAs in stable dosages.  
 
 
3. To investigate whether or not a prolonged 12-week exposure to mirtazapine could 
further improve neurocognition in patients with schizophrenia with no or only a sub-
optimal response to different FGAs in stable dosages. 
 
 
4. To determine whether or not 12-week mirtazapine treatment is associated with any 
improvement in clinical symptoms of patients with schizophrenia with no or only a 
sub-optimal response to different FGAs in stable dosages. 
 
 
?
?
?
 
 
 
?
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Patients?and?Methods?
 
 
Study design 
 
This study was the neurocognitive arm of a larger single-center, randomized, add-on, 
double-blinded, placebo-controlled study. Study participants were recruited from the 
Psychiatric Hospital and the Day Treatment Unit of the Psychoneurological Dispensary in the 
Karelian Republic, Petrozavodsk, Russia.  
 
Patients who fulfilled all selection criteria were enrolled into the trial. After a one-week 
single-blind placebo run-in period, patients were randomized to receive either mirtazapine 
30 mg or placebo every night at bedtime (QHS) in a double-blinded paradigm for 6 weeks 
(Studies I and II). Subsequently, patients who were willing to continue, and who were eligible 
to participate in an extension phase, entered the 6-week open-label phase, where they also 
received mirtazapine 30 mg QHS (Studies III and IV).  Study drug codes for the double-blind 
phase were revealed only after all participants had completed both phases of the study, and 
after the database was closed.  
 
 
Inclusion and exclusion criteria 
  Inclusion?criteria?
 
Patients of the study were of both genders, and included both in- and out-patients who 
fulfilled the following criteria: 
1) An age between 18 - 65 years, 
2) A diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or 
undifferentiated), as determined by the DSM-IV (American Psychiatric Association 1994), or 
schizoaffective disorder (depressive type), 
3) Currently receiving one or more FGA, at a cumulative daily dose of at least 200 mg 
chlorpromazine equivalents which had remained unchanged (also in terms of dosage) for at 
least six last weeks prior to screening. This criterion was extended to eight weeks for depot 
antipsychotics, 
4) Presenting less than optimal clinical outcome; i.e., suffering from either positive or 
negative symptoms, where a disability due to only general symptoms was insufficient for 
inclusion. This insured that the resulting illness was at least of moderate severity (i.e., a 
moderately ill rating of 4 or more on the Clinical Global Impression Scale (CGI) severity item) 
(Guy 1970), 
5) The clinical condition remained stable during the six weeks prior to the baseline visit, 
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6) The patient had a level of understanding that made reasonable cooperation with the 
investigator possible,  
7) A written informed consent given by the patient. 
 Exclusion?criteria?
 
1) A previous allergy or a serious adverse event due to mirtazapine, 
2) A history of unresponsiveness to a previous trial with mirtazapine at a daily dosage of 30 
mg or more during four or more weeks, augmented to the patient’s current or earlier 
conventional antipsychotic medication, 
3) A previous lack of response to another antidepressant (e.g.; mianserine, trazodone, or 
nefazodone,) that has affinity to postsynaptic 5-HT2 receptors, which were used at sufficient 
dosages during four weeks or more, 
4) Current atypical antipsychotic medication (e.g.; clozapine, risperidone, olanzapine, 
sertindole, quetiapine, zotepine, ziprasidone.) 
5) A previous non-response to either clozapine or other atypical antipsychotics, 
6) A medical or neurological illness, or drug treatment that might cause a serious risk for the 
patients, or bias the assessment of their clinical or mental status (e.g.; serious unstable 
physical illness, epilepsy, “organic” brain syndrome, etc.), 
7) A history of current bipolar disorder or schizoaffective disorder, bipolar type (patients 
with schizoaffective disorder, depressive type were able to participate in the study). 
8) Substance addiction or abuse during the last three months prior to screening, 
9) Poor medication compliance that is clearly predictable, 
10) Suicidality, 
11) For women of child-bearing age; pregnancy, lactation, or an inability or unwillingness to 
use medically acceptable methods of contraception during the study, 
12) Treatment with any antidepressant, mood stabilizer, systematic (i.e., four or more times 
within one week) use of sumatriptan, naratriptan, zolmitriptan, or drugs with a similar 
mechanism of action, or either buspiron or drugs with a similar mechanism of action within 
four weeks (for fluoxetine, six weeks) prior to baseline. Inadvertent use of any above-listed 
drugs for the treatment of migraine was prohibited on the day of clinical assessment, or just 
before the assessment, 
13) Treatment with antipsychotic drugs other than those currently used within the 6 weeks 
prior to baseline, 
14) Treatment with benzodiazepines as follows:  
- Systematic use (i.e., four or more times weekly) of any benzodiazepines at any dosage 
during any of the last four weeks prior to baseline, if they have been used for less than two 
months. However, systematic use of benzodiazepines was permitted if this treatment was 
considered to be absolutely necessary, and if they had been using benzodiazepines during 
two or more months before baseline in stable daily dosages not exceeding 30 mg of 
diazepam, or equivalent dosages of other benzodiazepines, 
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- Accidental use (i.e., three or less times weekly) of benzodiazepines in daily dosages 
exceeding 30 mg of diazepam or equivalent dosages of other benzodiazepines. Use of 
benzodiazepines on the day of clinical assessment was prohibited before the assessment, 
15) Electroconvulsive therapy (ECT) within three months prior to baseline, 
16) Any clinically meaningful abnormality identified during the physical examination, or 
laboratory screening that was likely to interfere with the conduct of the study. 
 
 
Main study procedures 
 Demographic?data?collection?
 
The following data were derived from the patient and primary clinical documents: 
• date of birth 
• diagnosis (DSM-IV) 
• time of onset of the illness 
• date of onset of the current episode 
• number of previous psychotic episodes 
• date of hospitalization and its reason (if appropriate) 
• the date and the reason of possible drop-out 
• history of antipsychotic medication use (what antipsychotics, in what dosages, and for how 
a long, and if have they been used prior to the study). 
 Neuropsychological?assessment???
 
At weeks 0, 6, and 12, a trained psychologist performed individual neuropsychological 
examinations to determine neurocognitive function. Russian translations (latest available 
versions) of commonly used and validated neuropsychological tests were employed to cover 
a broad range of neurocognitive domains (Szöke et al. 2008).  
 
To ensure the same level of basic intelligence functions in both study groups, all patients 
were first tested with four subtests of the Wechsler Adult Intelligence Scale – Revised (WAIS-
R; Wechsler 1981). When assessing general intelligence domains, verbal intellectual function 
was measured with the Information and Similarities subtests, and non-verbal intelligence 
was evaluated with the Block Design and Digit Symbol subtests of the WAIS-R. Three 
subscales of the WMS (Wechsler 1945) were used to assess memory, where verbal memory 
was evaluated with the Logical Memory and Verbal Paired Associations subscales, and visual 
memory with the Visual Reproduction subscale. Executive functions were assessed with the 
Trail Making Test, part B (TMT-B) (Lezak, 1995; Reitan & Wolfson 1985), the Stroop coloured 
colour-names part of the Stroop test (Stroop words; Jensen & Rohwer 1966; Lezak 1995) and 
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the Digit Symbol subtest of the WAIS-R (Lezak 1995). To investigate initiation and conduct 
strategic mnemonic processing, verbal fluency was examined with a semantic category 
(animals) and letter word-list generation (words beginning with K) within a time limit of 60 
seconds (Lezak 1995). The Block Design of WAIS-R was used to evaluate visual-spatial ability 
and fluency. General mental speed/attention control was evaluated with the Trail Making 
Test, part A (TMT-A) (Reitan & Wolfson 1985) and with the naming of coloured dots in the 
Stroop test (Stroop Dots; Jensen & Rohwer 1966; Lezak 1995). All neuropsychological tests 
were efficacy variables in this study. Table 2 displays the use of different neuropsychological 
assessment scales in Studies I-IV. 
 
Clinical assessments?
 
Clinical assessments were carried out at week –1 (screening), week 0 (baseline) and after 1, 
2, 4, 6, 7, 8, 10, and 12 weeks of treatment. Clinical efficacy was evaluated by PANSS (Kay et 
al. 1987), CGI and the Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al. 
1993).  The Patient Global Impression Scale (PGI) (Guy 1976) was used to further analyze the 
patients’ subjective attitudes to the study medication. The Simpson-Angus Scale for 
Extrapyramidal Side-effects (SAS) was used to investigate the FGA-induced extrapyramidal 
symptoms (Simpson and Angus 1970).  Different clinical assessment scales used in Studies I-
IV are shown in Table 2. 
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Table 2. Neuropsychological and clinical assessment scales used in Studies I-IV 
 
Neuropsychological/clinical assessment scale Reference I II III IV 
CDSS, Calgary Depression Scale for Schizophrenia Addington at al.1993  x    
CGI, Clinical Global Impression Scale Guy 1976    x 
Letter word-list generation (words beginning with K) Lezak 1995 x   x   
PANSS, The Positive and Negative Syndrome Scale Kay et al. 1987  x   x 
PGI, Patient Global Impression Scale Guy 1976    x 
SAS, Simson-Angus Scale for Extrapyramidal Side Effects Simson and Angus 
1970 
 x   x 
Semantic Category (animals) Lezak 1995 x   x   
Stroop test, coloured colour-names part Lezak 1995; Reitan 
and Wolfson 1985 
x   x   
Stroop test, naming of coloured dots Jensen and Rohwer 
1966; Lezak 1995 
x x x  
TMT-A, Trail Making Test, part A Reitan and Wolfson 
1985 
x   x   
TMT-B Trail Making Test, part B Reitan and Wolfson 
1985; Lezak 1995 
x   x   
WAIS-R, Wechsler Adult Intelligence Scale, Block Design  Wechsler 1981 x x x  
WAIS-R, Wechsler Adult Intelligence Scale, Digit Symbol Subtest Wechsler 1981; Lezak 
1995 
x   x   
WAIS-R, Wechsler Adult Intelligence Scale, Information and 
Similarities Subtest 
Wechsler 1981 x     
WMS, Wechsler Adult Memory Scale, Logical Memory Subscale Wechsler 1945 x   x   
WMS, Wechsler Adult Memory Scale, Visual Reproduction Subscale Wechsler 1945 x   x   
WMS, Wechsler Adult Memory Scale, Verbal paired Associates 
Subscale 
Wechsler 1945 x   x   
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Safety and tolerability assessments 
 
Physical examination and laboratory tests (including complete blood count, fasting levels of 
glucose and total cholesterol) were carried out at screening and end-point. In addition, the 
participants were asked about any adverse events while on the study medication. 
 
  Concomitant?medications?
 
The following medications were not allowed during the study: 
1) Antidepressants other than the study drug (mirtazapine) as defined in this protocol. 
2) Antipsychotics other than the patient’s pre-existing FGA(s). 
3) Mood stabilizers. 
4) Systematic (i.e., four or more times within one week) use of sumatriptan, naratriptan, 
zolmitriptan or drugs with a similar mechanism of action. Accidental use of these drugs was 
prohibited on the days of clinical assessments and before the assessments. 
5) Buspiron or drugs with a same kind of mechanism of action. 
6) Benzodiazepines: 
Regular use (i.e., four or more times weekly) of any benzodiazepines at any dosage was 
prohibited if the patient not received any benzodiazepine for two or more months prior to 
baseline (week 0) in stable dosages not exceeding 30 mg of diazepam or equivalent. The 
investigators were encouraged to keep the regular, pretrial benzodiazepine medication 
unchanged during the study. A decrease in dosages was, however, permitted due to ethical 
reasons, while any increase was not allowed . 
Accidental use (i.e., three or less times weekly) of a benzodiazepine in daily doses that 
exceeded 30 mg of diazepam or equivalent was not allowed. Accidental use of 
benzodiazepines at any dosage was prohibited on the days of clinical assessments and 
before these assessments. 
7) If necessary, zopiclon, zolpidem and zaleplon were permitted as hypnotics, in dosages not 
exceeding recommendations of the manufacturer. 
 
 
Statistical methods 
 
Analyses were carried out on a Modified Intent-to Treat (MITT) basis, with Last Observations 
Carried Forward (LOCF). False discovery rate (FDR) was applied to correct for multiple 
testing, and FDR controlled for the expected proportion of incorrectly rejected null 
hypotheses (type I errors). The q-value software 
(http://genomics.princeton.edu/storeylab/qvalue/manual.pdf) was employed for the FDR 
procedure, according to Storey (2002). 
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Cross-sectional statistical differences between the study groups were tested by using Chi-
Square (Studies I, III, IV) or by Fisher's exact test (Study IV) for categorical variables. Cross-
sectional statistical differences between the study groups were analyzed by using the Mann-
Whitney U-test (Studies I and III) and by the independent samples t-test (Study IV) for 
continuous variables.  
 
Possible within-group changes in efficacy variables over time were assessed with the 
Wilcoxon test, and differences between treatments over time were evaluated with the 
Mann-Whitney U-test (Studies I and III). Within-group changes in the efficacy variables over 
time were analyzed by the paired sample t-test (Study IV). Spearman’s correlation 
coefficient was used post hoc to investigate possible associations between longitudinal 
changes in neurocognitive measures (Study I).  
 
A path analysis model was used for the identification of predictors and mediators In Study II. 
Path analysis method has important advantages over multiple regressions, and served as a 
method that allowed testing a system of regression equations where variables can serve as 
predictors, mediators and outcome. This also enabled multiple outcomes to be studied at 
the same time and the parsing of effects into their direct, indirect and total components. A 
robust maximum likelihood (MLR) estimator was used as an estimator, to correct for any 
non-normality in the variable distributions, in addition to providing an unbiased estimate of 
the standard errors (Muthén and Muthén 1998–2010). Each path analysis model was first 
conducted by including all possible paths, as shown in Figure 3. Because of the small sample 
size (n=19 in the mirtazapine group and n=18 in the placebo group), the final model for each 
mediator-/outcome-combination was calculated with a minimal number of paths from  
“other baseline variables than mirtazapine” to the mediator, and the outcome that was not 
statistically significant in the initial model. 
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Figure 3 
A path-analytic approach was used to evaluate for possible predictors and mediators of a 
putative enhancing effect from adjunctive mirtazapine on neurocognition in schizophrenia. 
The path analysis model included all possible paths from treatment to outcome. 
  
 
In Studies I, III, and IV, a p-value less than 0.05 was considered to be statistically significant. 
All analyses in Studies I, III, and IV were performed by using SPSS for Windows 14.0 software. 
In Study II, a statistical significance of p < 0.10 was applied instead of the normal p < 0.05, 
due to the small sample size, and this was decided a priori. Mplus 5.21 software was used to 
perform the path analysis in Study II. 
 
 
Ethics 
 
This study was made in compliance with the current version of the Declaration of Helsinki, 
Guideline for Good Clinical Practice (ICH_GCP) and with the current National Regulations in 
the Russian Federation Karelian Republic. The study protocol was considered and approved 
by the Ethical Committee of the Karelian Republic and the local Institutional Review Board 
before the start of the trial. After a complete description of the study, a written informed 
consent was received from each patient. Individuals were allowed to withdraw their consent 
at any time. Patients were recruited only if add-on mirtazapine treatment was considered 
appropriate and useful from a clinical point of view.  
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Results?
 
 
Study outline, baseline demographics with neurocognitive and clinical profiles 
 
 
This study included a double-blind, add-on, randomized, placebo-controlled, with a 6-week 
main period and an open-label 6-week extension phase. Studies I and II are based on data of 
the double-blind main phase (6 weeks), and Studies III and IV incorporate data from both the 
double-blind main phase (6 weeks) and the extension phase (6 weeks).  
 
Table 3 displays the number of patients included in Studies I-IV. Of the 46 individuals 
screened, 41 were randomized. In Studies I and II, after randomization, one patient allocated 
to placebo was excluded due to a protocol violation and one patient (placebo assigned) 
withdrew consent. Two patients, one in each study group, were excluded due to their 
inability to perform in neurocognitive tests. Thus, a modified intent-to-treat population 
resulted in 19 individuals in the mirtazapine and 18 in the placebo groups in Studies I and II.  
 
The study population in Study III consisted of completers from the 6-week double-blind 
phase who were capable and willing to proceed to the 6-week open label phase, and who 
were capable of at least one assessment after exposure to mirtazapine treatment. One 
individual in the continuation group could not be tested at week 12 and was excluded. Thus, 
data on 18 patients were analyzed at week 12, both for the continuation group (12-week 
mirtazapine exposure) and for the switch group (initially 6 weeks on placebo and thereafter 
6 weeks on mirtazapine).  
 
In Study IV, all 20 individuals originally assigned to the mirtazapine group completed the 
extension phase. In the placebo group, out of 21 assigned to placebo, four patients withdrew 
and one was excluded due to a protocol violation. 
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Table 3. Participant assignment in Studies I-IV 
 
 Studies I 
and II 
(n) 
Study III 
(n) 
Study IV 
(n) 
Screened  46 46 46 
Randomized 41 41 41 
Assigned mirtazapine  20 20 20 
Assigned placebo 21 21 21 
Analyzed mirtazapine double-blind phase, week 6 19 x x 
Analyzed placebo double-blind phase, week 6 18 x x 
Analyzed continuation group mirtazapine open-label phase, week 12 x 18 20 
Analyzed switch from placebo to mirtazapine group open-label phase, week 12 x 18 16 
 
 
 
There were no differences between the mirtazapine and placebo groups at baseline in age 
(44.05?9.00 vs. 48.11?9.95 years, p=0.19), gender/males (52.6% vs. 50.0%, p=0.87), in-
patient status (52.6% vs. 33.3%, p=0.24), duration of illness (23.84?6.40 vs. 24.44?9.45 
years, p=0.29), antipsychotic dose in chlorpromazine equivalents (319.21?115.31 vs. 
300.83?154.26, p=0.25) or number of previous antipsychotics (8.74?2.76 vs. 7.78?3.28, 
p=0.34). 
 
 
No difference emerged in the neuropsychological performance tests (WAIS-R, WMS, Stroop 
test, TMT, Word fluency) (Table 4) or clinical characteristics (PANSS total 105.63?10.26 vs. 
97.50?13.64 points, p=0.15; PANSS positive 22.32?4.14 vs. 18.67?5.18 points, p=0.13; 
PANSS negative 30.32?3.99 vs. 28.50?3.93 points, p=0.32; PANSS general 53.00?6.37 vs. 
50.33?7.44 points, p=0.37) at baseline between the mirtazapine and placebo groups. 
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Table 4. Baseline neuropsychological profile of the study population (completers of the 
double-blinded phase)  
 
 Mirtazapine (n=19) 
mean (S.D.) 
Placebo (n=18) 
mean (S.D.) 
Test statistics 
WAIS-R, information (points) 15.16 (5.94) 13.72 (4.60) z=1.16, p= 0.404 
WAIS-R, similarities (points) 13.58 (5.48) 12.39 (3.18) z=0.58, p=0.497 
WAIS-R, block design (points) 28.28 (8.66) 27.17 (9.76) z=0.32, p=0.564 
WMS, digit symbol (points) 25.28 (9.72) 23.24 (8.33) z=0.79, p=0.444 
WMS, digit span forward (points) 5.32 (0.89) 5.11 (1.08) z=1.01, p=0.421 
WMS, digit span backward (points) 3.72 (0.96) 3.72 (0.83) z=0.19, p=0.614 
WMS, digit span total (points) 8.84 (1.80) 8.83 (1.62) z=0.48, p=0.536 
WMS, logical memory (points) 8.47 (4.23) 8.28 (4.01) z=0.11, p=0.638 
WMS, logical memory delayed (points) 6.78 (3.52) 6.22 (3.77) z=0.32, p=0.564 
WMS, verbal paired associations (points) 17.84 (7.57) 19.67 (5.57) z=0.61, p=0.497 
WMS, verbal paired associations delayed (points)  6.78 (2.46) 7.17 (2.18) z=0.35, p=0.559 
WMS, visual reproduction (points)    6.83 (2.94) 6.56 (3.81) z=0.03, p=0.659 
WMS, visual reproduction delayed (points) 4.59 (2.90) 3.94 (3.35) z=0.58, p=0.497 
Stroop Dots (84) (time) 122.05 (55.40) 108.39 (45.56) z=0.91, p=0.437 
Stroop Dots (84) (number of mistakes) 1.11 (1.37) 1.00 (1.91) z=0.59, p=0.497 
Stroop coloured words (84) (time) 152.94 (61.13) 192.41 (119.95) z=0.84, p=0.438 
Stroop coloured words (84) (number of mistakes) 2.44 (2.01) 3.29 (2.62) z=0.91, p=0.437 
TMT-A (time)  97.11 (53.90) 107.41 (54.71)  z=0.78, p=0.444 
TMT-A (number of mistakes) 0.11 (0.32) 0.24 (0.75) z=0.12, p= 0.638 
TMT-B (time)  152.47 (65.08) 162.71 (78.47)  z=0.38, p=0.559 
TMT-B (number of mistakes) 1.59 (1.50) 1.35 (1.66) z=0.68, p=0.491 
Word fluency, letter words (points) 6.26 (3.02)  6.89 (2.68) z=0.83, p=0.438 
Word fluency, semantic (points)  7.79 (3.38)  9.17 (3.73) z=1.16, p=0.404 
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The effect of 6-week adjunctive mirtazapine on neurocognitive symptoms of 
schizophrenia (Study I) 
 
 
In Study I, after 6 weeks of treatment, when retests and initial tests were compared, 5/21 
cognitive parameters (i.e. WAIS-R Block Design, p=0.021; WMS Logical Memory, p=0.044; 
WMS Logical Memory Delayed, p=0.044; Stroop Dots, p=0.044; TMT-A, p=0.018) were 
significantly improved in the mirtazapine group, compared to 1/21 statistically significant 
parameters (WMS Logical Memory, p=0.039) in the placebo group (Table 5). No worsening 
was observed in any of the neurocognitive parameters in either of the study groups.  
 
Mirtazapine was better than placebo on the Block Design and Stroop Dots tests in the 
between-group comparisons (Table 5). The difference in the degree of change; i.e., the 
change while on mirtazapine minus that on placebo was 18.6% for Block Design and 11.1% 
for Stroop Dots (p=0.044 for both). This improvement was not associated with age, gender, 
duration of illness, out-or in-patient status, dose of antipsychotics or with improvements in 
negative, positive or general symptoms. Depression scores (item 20 of PANSS) were similar 
and not statistically significant between the mirtazapine and placebo groups at baseline 
(p=0.667). Changes in Block Design or Stroop Dots did not correlate with baseline depression 
scores (r=?0.08, p=0.649 and r=?0.085, p=0.629, respectively). 
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Table 5. Change in neurocognitive parameters between week 6 and baseline (Study I) 
 
 Change within 
continuation 
mirtazapine 
group  
(n=19), p-value 
Change within 
placebo  
group (n=18), 
p-value 
Change 
between 
groups, 
mirtazapine vs. 
placebo, 
p-value 
 
WAIS-R block design (points) p=0.021 p=0.313 p=0.044 
VMS digit symbol (points) p=0.437 p=0.347 p=0.543 
VMS digit span forward (points) p=0.421 p=0.438 p=0.494 
VMS digit span backward (points) p=0.206 p=0.528 p=0.327 
VMS digit span total (points) p=0.233 p=0.659 p=0.377 
VMS logical memory (points) p=0.044 p=0.039 p=0.588 
VMS logical memory delayed (points) p=0.044 p=0.200 p=0.438 
VMS verbal paired associations (points) p=0.123 p=0.496 p=0.404 
VMS verbal paired associations delayed (points) p=0.091 p=0.437 p=0.421 
VMS visual reproduction (points) p=0.206 p=0.559 p=0.421 
VMS visual reproduction delayed (points) p=0.065 p=0.072 p=0.614 
Stroop Dots (84) (time) p=0.044 p=0.525 p=0.044 
Stroop Dots (84) (number of mistakes) p=0.421 p=0.559 p=0.249 
Stroop coloured words (84) (time) p=0.164 p=0.421 p=0.543 
Stroop coloured words (84) (number of mistakes) p=0.208 p=0.497 p=0.444 
TMT-A (time) p=0.018 p=0.421 p=0.233 
TMT-A (number of mistakes) p=0.659 p=0.421 p=0.438 
TMT-B (time) p=0.053 p=0.659 p=0.091 
TMT-B (number of mistakes) p=0.421 p=0.540 p=0.614 
Word fluency letter words (points) p=0.199 p=0.659 p=0.169 
Word fluency semantic (points) p=0.313 p=0.421 p=0.168 
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Predictors and mediators of enhancing effect of adjunctive 6-week mirtazapine 
treatment on neurocognition (Study II) 
 
 
In Study II, a path model analyses revealed that add-on mirtazapine had an independent 
enhancing effect on the Block Design-measured visuo-spatial functioning. Overall, the fit was 
good in models that were conducted with no significant statistical differences between the 
models and data.  
 
 
Path model analysis results  
 
The results for each explored mediator are presented in Figure 4. The paths of mirtazapine 
? mediator, mirtazapine ? outcome and mediator ? outcome were always included in the 
final path analysis models, whether they were statistically significant or not. These paths are 
at all times of theoretical interest. A solid line indicates that the path is statistically 
significant, while a dashed line in the model designates that a path was not statistically 
significant. (nota bene; all figures and tables in this section are reprinted with permission). 
?
 Block?Design??
 Model?for?PANSS?negative?subscale?
 
Mirtazapine treatment indicated an independent effect on both the Block Design and 
negative symptoms (Figure 4 and Table 6). The change in negative symptoms did not 
mediate the improvement in Block Design. A better baseline level of Block Design 
functioning predicted less improvement in this particular test. 
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Figure 4. Model for PANSS negative subscale 
 
 
 
 
 
Table 6. Predictors and mediators of add-on mirtazapine-induced enhancement in Block Design 
measured neurocognitive function in schizophrenia- results of the path analysis; Model for PANSS 
negative scores.  
 
? = change (scores at week 0 minus scores at week 6) 
 
Path analysis model 
Predictor or 
mediator 
Value, ? 
(s.e.) 
 
t= p= 
(two-
tailed) 
Overall 
model fit, 
p= 
Model for PANSS negative scores 0.845 
 
Block Design, ? 
 
mirtazapine 2.87 
(1.58) 
1.81 0.070  
Block Design, 
baseline 
-0.18 
(0.08) 
-2.39 0.017 
PANSSn, ? -0.29 
(0.29) 
-0.98 0.328 
 
 
?
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?Model?for?PANSS?positive?subscale?
?
Mirtazapine treatment showed a direct effect on the Block Design and PANSS positive scores 
(Figure 5 and Table 7). The effect of mirtazapine on changes in the Block Design was also 
mediated by changes in PANSS positive scores. Higher values for changes in PANSS positive 
scores were associated with higher values in the Block Design. Higher antipsychotic doses 
and shorter durations of illness were associated with larger improvements in the Block 
Design. 
 
 
 
Figure 5. Model for PANSS positive subscale 
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Table 7. Predictors and mediators of add-on mirtazapine-induced enhancement in Block Design 
measured neurocognitive function in schizophrenia- results of the path analysis; Model for PANSS 
positive scores.  
 
? = change (scores at week 0 minus scores at week 6) 
 
Path analysis model 
Predictor or 
mediator 
Value, ? 
(s.e.) 
  
t= p= 
(two-
tailed) 
Overall 
model fit, 
p= 
Model for PANSS positive scores 0.791 
 
 
Block Design, ? 
 
mirtazapine 3.73 
(1.09) 
3.44 0.001  
duration of illness -0.23 
(0.06) 
-3.68 0.000 
 
FGA dose 0.01 
(0.01) 
2.29 0.022 
Block Design, 
baseline 
-0.22 
(0.08) 
-2.85 0.004 
PANSSp, ? 0.35 
(0.13) 
2.82 0.005 
 
 
 
 Model?for?PANSS?total?scale??????
?
 
Mirtazapine treatment showed an independent effect on both the Block Design and PANSS 
total scores (Figure 6 and Table 8). PANSS total scores, however, did not mediate the 
improvement in the Block Design. Better baseline functioning in the Block Design and longer 
duration of illness predicted only a minor improvement. Higher antipsychotic dosages 
predicted a larger improvement in the Block Design. 
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Figure 6. Model for PANSS total scale   
 
 
 
Table 8. Predictors and mediators of add-on mirtazapine-induced enhancement in Block Design 
measured neurocognitive function in schizophrenia- results of the path analysis; Model for PANSS 
total scores.  
? = change (scores at week 0 minus scores at week 6) 
 
Path analysis model 
Predictor or 
mediator 
Value, ? 
(s.e.) 
  
t= p= 
(two-
tailed) 
Overall 
model fit, 
p= 
Model for PANSS total scores 0.492 
 
 
Block Design, ? 
mirtazapine 2.99 
(1.06) 
2.82 0.005  
duration of 
illness 
-0.20 
(0.06) 
-3.17 0.002 
FGA dose 0.01 
(0.01) 
2.34 0.020 
Block Design, 
baseline 
-0.21 
(0.08) 
-2.59 0.010 
PANSSt, ? 0.04 
(0.04) 
1.00 0.317 
PANSSt, ? mirtazapine -10.30 
(3.18) 
-3.24 0.001 
?
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Models?for?CDSS?and?SAS?
 
Mirtazapine treatment was associated with an improvement in the Block Design, both 
directly and via the CDSS (Figure 7 and Table 9).  The same was true for the SAS in a separate 
model (Figure 7 and Table 9).  In both the Model for the CDSS and the Model for the SAS, 
better baseline functioning in the Block Design and longer duration of illness predicted 
smaller improvements in the Block Design, while higher antipsychotic dosages predicted a 
larger improvement. 
 
 
Figure 7. Models for CDSS and SAS 
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Table 9. Predictors and mediators of add-on mirtazapine-induced enhancement in Block Design 
measured neurocognitive function in schizophrenia- results of the path analysis; Models for CDSS 
and SAS.  
? = change (scores at week 0 minus scores at week 6) 
 
Path analysis model 
Predictor or 
mediator 
Value, ? 
(s.e.) 
  
t= p= 
(two-
tailed) 
Overall 
model fit, 
p= 
Model for CDSS 0.490 
Block Design, ? mirtazapine 3.17 
(1.09) 
2.92 0.004  
duration of 
illness 
-0.20 
(0.06) 
-3.38 0.001 
FGA dose 0.01 
(0.01) 
1.92 0.054 
Block Design, 
baseline 
-0.19 
(0.07) 
-2.62 0.009 
CDSS, ? 0.30 
(0.12) 
2.39 0.017 
CDSS, ? mirtazapine -1.85 
(0.95) 
-1.94 0.051 
Model for SAS 0.518 
Block Design, ? mirtazapine 3.50 
(1.09) 
3.22 0.001  
duration of 
illness 
-0.15 
(0.06) 
-2.77 0.006 
FGE dose 0.01 
(0.00) 
2.08 0.038 
Block Design, 
basline 
-0.20 
(0.07) 
-2.89 0.004 
SAS, ? 0.41 
(0.20) 
2.08 0.037 
SAS, ? mirtazapine -2.04 
(0.97) 
-2.10 0.036 
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?Stroop?Dots??
  
Results from the path model analysis show that mirtazapine treatment was not 
independently associated with an enhancement in the Stroop Dots for any model. In all 
models - except the model for SAS- better baseline performance (= smaller time) and higher 
dosages of FGAs predicted a minor improvement (= smaller drop in time) on the Stroop 
Dots. Of all measured parameters, only SAS mediated the effects of mirtazapine towards 
improvement in the Stroop Dots. In other words, decreases in the SAS scores were 
correlated with decrease in time in the Stroop Dots. 
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Effect of 12-week exposure to mirtazapine on neurocognitive symptoms of 
schizophrenia (Study III) 
 
 
In Study III,  patients who received mirtazapine in the double-blind phase, and continued on 
mirtazapine during the extension-phase (totally 12 weeks on mirtazapine), formed the 
“continuation group”.  Patients who were on placebo during the double-blind phase and 
received mirtazapine only during the extension-phase (totally 6 weeks on mirtazapine) 
formed the “switch group”.  
 
Those who switched from placebo to open label mirtazapine treatment achieved similar 
results in the 6 following weeks as the mirtazapine-treated individuals who had their first 6 
weeks on mirtazapine treatment.  
 
During the extension phase, 12 out of the 21 neurocognitive measured parameters 
improved in the continuation group, while 6 parameters showed improvement in the switch 
group (Table 10). 
 
From week 0 to week 12 the continuation group demonstrated improvements in 17/21 
parameters, and in 8/21 parameters for the switch group (Table 10).  Twelve weeks of 
mirtazapine treatment indicated an advantage over the shorter, 6-week mirtazapine 
treatment on Stroop Dots time and TMT-B, according to the number of mistakes (t = -2.562, 
p = 0.035 and t = -2.42, p = 0.043, respectively) (Table 10).   
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Table 10.  Change in neurocognitive parameters after the shift from 6 weeks double-blind 
treatment, with either mirtazapine or placebo, to 6 weeks (weeks 6 to 12, extension phase) 
treatment with open-label mirtazapine (Study III). 
 
 
Change within 
continuation 
group, (n=18), 
wk 6-12, 
p-value 
Change within 
switch group, 
(n=18), 
wk 6-12,   
p-value 
Change within 
whole 
population, 
(n=36), 
wk 6-12, 
p-value 
Change within 
continuation 
group, (n=18), 
wk 0-12, 
p-value 
Change within 
switch group, 
(n=18), 
wk 0-12, 
p-value 
Change in 
continuation 
vs. change in 
switch group  
wk 0-12, 
p-value 
WAIS-R block design (points) 0.529 0.044 0.397 0.023 0.006 0.256 
VMS digit symbol (points) 0.001 0.18 0.006 0.024 0.073 0.544 
VMS digit span forward 
(points) 
0.028 0.034 0.006 0.009 0.020 0.541 
VMS digit span backward 
(points) 
0.133 0.334 0.117 0.017 0.490 0.104 
VMS digit span total (points) 0.030 0.104 0.014 0.006 0.124 0.272 
VMS logical memory (points) 0.052 0.503 0.196 0.009 0.014 0.566 
VMS logical memory delayed 
(points) 
0.039 0.052 0.006 0.001 0.026 0.257 
VMS verbal paired 
associations (points) 
0.118 0.028 0.013 0.012 0.050 0.503 
VMS verbal paired 
associations delayed (points) 
0.009 0.450 0.104 0.001 0.144 0.147 
VMS visual reproduction 
(points) 
0.014 0.132 0.009 0.023 0.331 0.231 
VMS visual reproduction 
delayed (points) 
0.035 0.273 0.043 0.001 0.031 0.544 
Stroop Dots (time) 0.045 0.209 0.042 0.001 0.073 0.035 
Stroop Dots (number of 
mistakes) 
0.272 0.531 0.503 0.14 0.531 0.203 
Stroop coloured words (time) 0.036 0.014 0.001 0.006 0.044 0.450 
Stroop coloured words 
(number of mistakes) 
0.290 0.104 0.079 0.073 0.334 0.431 
TMT-A (time) 0.032 0.024 0.001 0.001 0.041 0.561 
TMT-A (number of mistakes) 0.290 0.290 0.577 0.290 0.199 0.133 
TMT-B (time) 0.013 0.006 0.001 0.001 0.294 0.124 
TMT-B (number of mistakes) 0.06 0.542 0.150 0.006 0.577 0.043 
Word fluency letter words 
(points) 
0.045 0.050 0.014 0.032 0.031 0.503 
Word fluency semantic 
points) 
0.345 0.080 0.069 0.079 0.334 0.334 
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Effect of 12-week exposure to mirtazapine on clinical symptoms of schizophrenia 
(Study IV) 
 
In Study IV, the first 6-week mirtazapine exposure resulted in a similar total PANSS score 
change in the continuation group (i.e., weeks 0-6) as in the switch group (i.e., weeks 6-12); 
i.e., 15.63 vs. 13.3, p=0.495.   
 
PANSS total, PANSS positive, PANSS negative, PANSS general, CGI, and SAS significantly 
improved with mirtazapine treatment in the continuation and switch groups (p<0.0001) 
during the extension phase. CGI severity scale did not improve in the continuation group 
(p=0.163), but did improve in the switch group (p<0.0001).  In the total population (pooled 
data for switch and continuation groups), all parameters that were measured improved with 
statistical significance. The effect size of this change was 0.94 (CI 95%=0.45?1.43), as 
determined by PANSS total score. 
 
Patients who were on mirtazapine during both the 6-week double-blind and the 6-week 
open phases showed greater improvement in positive symptoms (29.6% versus 21.2%, 
p=0.027) than those who were on mirtazapine during open-label extension phase only.  
?????????????????????????????????????????????????????????????????????????????????
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Discussion?
 
 
The main findings 
  
This study was designed to explore the efficacy of 6-week mirtazapine add-on therapy with 
different FGAs in patients with schizophrenia. Neurocognitive functions were studied to 
evaluate the additional effects of a prolonged 12-week exposure to mirtazapine, and to 
determine whether or not this improved neurocognition in these patients. Predictors and 
mediators of an enhancing effect from adjunctive 6-week mirtazapine treatment on 
neurocognition were also explored. In addition, this study focused on whether or not 12-
week mirtazapine treatment is associated with an improvement in clinical symptoms in 
patients with schizophrenia. 
  
The population for this study comprised patients who suffered from a prolonged disease and 
had a previous history of insufficient response to antipsychotic medications. During the 
study enrollment, patients were at a moderately stable stage of their disease, and their FGA 
treatment had remained unchanged for at least six weeks prior to screening. Overall, 
patients were highly symptomatic and had severe neurocognitive impairments.  
 
This study is the first to report a favorable effect of a mirtazapine-FGA combination on 
neurocognitive impairments in a RCT study design. Adjunctive mirtazapine treatment not 
only enhanced neurocognition, but also had some desirable effects on the overall clinical 
symptomatology in chronic schizophrenia. 
 
 
 
Effects of add-on mirtazapine on neurocognition in schizophrenia  
 
In the first part of this study, a statistically positive effect was achieved when mirtazapine 
was added to FGAs, and compared to placebo, in neurocognitive domains of visual-spatial 
ability and general mental speed/attention control according to results from the Block 
Design and Stroop Dots, respectively. The difference in the degree of change (i.e., the 
change from mirtazapine minus that of placebo) was almost 20% in the Block Design and 
more than 10% in Stroop Dots. Improvements were not related to either the changes in 
psychopathology or depression.  In addition, 5 out of 21 measured parameters improved 
with statistical significance in within-group analyses after mirtazapine vs. only one 
parameter with placebo. 
 
Delle Chiae et al. (2007) published the first clinical study with add-on mirtazapine in 
schizophrenia. The duration of this study was 8 weeks, with an open label study design and 
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included only 15 outpatients. In their study mirtazapine was added to clozapine and 
reported to improve neurocognition. Contrary to the findings of our study, Delle Chiae and 
co-authors (2007) reported an improvement in both immediate and delayed memories with 
the mirtazapine-clozapine combination. Nonetheless, visual-spatial abilities and 
psychopathological parameters remained unchanged.  
 
The difference in the results between these two studies might be due to a difference in the 
study samples.  For example, Delle Chiae et al. (2007) studied stable outpatients with a ten 
year duration of illness of, while the patients in our study were highly symptomatic in-
patients with a 20 year duration of illness.  Also, the different receptor affinity profiles from 
the mirtazapine-FGAs combinations (i.e., inhibition of a wide range of receptors, in addition 
to D2) in our study vs. the mirtazapine-clozapine combination may also account for some 
significant variation (i.e., through an additional inhibition in only a limited number of 
receptors for clozapine; e.g., alpha2).  Other methodological issues are also worth 
mentioning; e.g., different neuropsychological measures and a smaller sample size or the 
open design of the earlier study may also provide reasons for different profiles of positive 
results between these two studies.  
 
Both the Block Design and Stroop dots tests are, at least in some way, related to general 
executive functions, which were also measured by TMT-B in this study.  In line with this 
assumption, TMT-B also tended to favor mirtazapine (improvement by 13% with mirtazapine 
vs. worsening by 4.8% with placebo). However, this difference did not reach statistical 
significance after the FDR correction (p=0.091).   
 
The actual mechanism for a potential neurocognitive enhancing effect of mirtazapine in 
schizophrenia remains unknown, but it may be elucidated from its receptor binding profile.  
Like most SGAs, mirtazapine could also increase prefrontal dopaminergic and noradrenergic 
activity via 5-HT2A or 5-HT2C receptor blockade, as demonstrated in animal models (Liegeois 
et al. 2002; Meneses 2007; Zhang et al. 2000), and thus improve neurocognitive 
performance.  Secondly, 5-HT3 receptor modulation by mirtazapine could also improve 
neurocognition (Akhondzadeh et al. 2009), presumably through increased release of 
acetylcholine (Ramirez et al. 1996). Thirdly, mirtazapine might improve neurocognition as a 
result of the indirect agonism of 5-HT1A receptors (Sumiyoshi et al. 2007). Moreover, 
mirtazapine is a more potent alpha-2 receptor antagonist than clozapine, which may explain 
its additional neurocognition-enhancing effect, even if it is added to clozapine (as in the 
study reported by Delle Chiae et al. 2007). The alpha-2 receptors remain an important target 
for neurocognitive research and its down-regulation may enhance neurocognition through a 
noradrenaline-mediated modulation of response to environmental stimuli (Friedman et al. 
2004). Furthermore, alpha-2 receptor antagonism seems to boost hippocampal 
neurogenesis (Rizk et al. 2006). Also, mirtazapine may actually boost levels of brain-derived 
neurotrophic factor (BDNF) Rogoz et al. 2005), which is a major mediator of neurogenesis 
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and neuroplasticity. Correspondingly, those who suffer from schizophrenia often have 
abnormally low BDNF serum levels (Rizos et al. 2008).   
 
Due to contemporary and large independent studies (Jones et al. 2006; Lieberman et al. 
2005; Tiihonen et al. 2006), FGAs may return to everyday psychopharmacological use in the 
future, especially if mirtazapine-FGA combinations become established as neurocognitive 
enhancers in schizophrenia.  The patents for both FGAs and mirtazapine have already 
expired, and are now relatively inexpensive, which is an important issue of enlarging 
significance.   
 
These beneficial neurocognitive effects of mirtazapine did not depend on baseline 
demographic, clinical parameters or its antidepressive effects. The most significant changes 
were seen in the positive symptoms domain, which appears to be independent of 
neurocognition (Heydebrand et al. 2004). The commonly experienced sedative effect of 
mirtazapine did not seem to prevent the development of its neurocognitive effects, at least 
by the endpoint (week 6) when the sedative effect of mirtazapine should have already 
weakened through the development of pharmacological tolerance (Ramaekers et al. 1998).   
 
  
It is important to note that since mirtazapine binds to multiple types of receptors, and the 
affinity of mirtazapine to these different receptor types is differential (see Anttila & 
Leinonen 2001). Thus, it is possible that lower doses of mirtazapine have qualitatively (and 
not just quantitatively) different add-on effects, when compared to the dosages that are 
typically given in the clinical context such, as the 30 mg/d dose utilized in the present study. 
  
 
Predictors and mediators of mirtazapine-induced cognitive enhancement 
in schizophrenia - a path model investigation 
 Block?Design??
  
In this part of the present study, mirtazapine treatment demonstrated a noticeable, (35 – 38 
%) independent and direct beneficial effect on the visuo-spatial ability, as measured by the 
Block Design in all path analysis models. 
 
Alterations in the PANSS positive, CDSS and SAS scores mediated the effect of mirtazapine 
on the visuo-spatial ability, as measured by the Block Design, while changes in the PANSS 
negative or PANSS total scores did not. Higher dosages of FGAs and shorter duration of 
illness predicted more noticeable improvement in the Block Design in all models except for 
one of the PANSS negative scores. A better baseline level of the Block Design predicted less 
improvement with add-on mirtazapine treatment.  
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Even though the PANSS positive, CDSS and SAS scores were better in these patients, the 
relationship of these scores to improvement in the Block Design was opposite. This means 
that a lesser degree of improvement in these clinical measures relates greater 
enhancements in the Block Design. Neither the interrelationship nor real life relationship 
between neurocognitive dysfunctions and clinical symptoms of schizophrenia are entirely 
understood.  Particularly negative symptoms have been the focus of neuropsychological 
examinations, as these symptoms have a tendency to overlap with neurocognitive deficits. 
 
Some researchers suppose that neurocognition and clinical symptoms are independent 
domains of schizophrenia (Green 1996; Harvey et al. 2006; Dominguez et al. 2009), while 
others maintain that neurocognitive deficits are secondary to clinical symptoms (Kerns and 
Berenbaum 2002; Nieuwenstein et al. 2001). 
 
A current systematic review (Dominguez et al. 2009) and a later publication by Ventura et al. 
(2009) demonstrate that negative symptoms are significantly associated with cognitive 
deficits, while positive and depressive dimensions of psychopathology are not.  However, in 
the CATIE study published by Keefe et al. (2007), neurocognitive enhancement was 
evidently, even if modestly, associated with symptom reduction in all PANSS dimensions. 
 
The current study presents the mediation of positive neurocognitive effects from 
mirtazapine via changes in positive, depressive, and parkinsonism symptoms, with the 
absence of any statistically significant relationship between an improvement in 
neurocognition with improvements in negative symptoms. This result may be due to the 
particular features of our study sample.  Patients in our study were chronically ill and 
severely psychotic, and the results showed the greatest improvements in positive and 
depressive symptoms (Joffe et al. 2009; Terevnikov et al. 2011). Additionally, an inverse 
relationship was seen between improvements in the Block Design results, and that a similar 
relationship between the positive, depressive and also parkinsonism symptoms might be 
entirely due to statistical reasons; i.e., the so-called regression to the mean phenomenon 
(Barnee et. al. 2005). If so, this means that in the beginning low clinical symptom scores in 
some patients could only allow for a lesser drop in clinical ratings, as the result of a ceiling 
effect, while their capacity for neurocognitive improvement could be higher than their more 
symptomatic matching parts. The probable role of clinical mediators in the effects of 
mirtazapine on neurocognition endures, at least somewhat, and requires more studies with 
statistical path analytical methods of larger and more varied patient populations.  
FGAs tend to impair neurocognition in schizophrenia, at least when high dosages are used 
(Keefe et al. 2007). In the present study, higher dosages of FGAs predicted a favorable effect 
from mirtazapine on the Block Design. In other words, mirtazapine seemed to remediate the 
unpleasant neurocognitive effect of FGAs on neurocognition. 
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According to a recent meta-analysis (Szöke et al. 2008), the remaining capacity for 
neurocognitive recovery in patients with long-term schizophrenia is limited. Consequently, it 
was not surprising to find in our study that the duration of illness correlated negatively with 
mirtazapine-induced neurocognitive improvement in most path analysis models. This could 
mean that the more extended duration of the illness, the more likelihood of cognitive 
deterioration, which seems to be more or less treatment resistant. One explanation for this 
effect might be that schizophrenia has often been considered as a disorder of connectivity 
between components of large-scale brain networks (Lynall et al. 2010). Consequently, there 
may be impaired interactive connectivity between different brain regions, which could cause 
executive dysfunctions and dysfunctions between different domains of neurocognition, and 
subsequent metacognitive problems.   
 Stroop?Dots?
 
Mirtazapine did not have an independent effect on the Stroop Dots. Higher dosages of FGAs 
predicted a minor improvement (= smaller drop in time) on the Stroop Dots test, and 
positive change in the SAS scores did mediate the effect of mirtazapine treatment on the 
Stroop Dots. This means that mirtazapine-induced improvements in general mental speed 
and attention control, as measured by Stroop Dots, were most likely indirect and due to an 
improvement in the FGA-related symptoms of parkinsonism, thus resulting in a better 
naming speed in this test. 
 
 
 
Effects of prolonged 12-week adjunctive mirtazapine  
  
After the six week extension phase of previous 6-week double blind phase, both groups 
showed significant improvements on several neurocognitive tests. Moreover, the prolonged 
treatment with mirtazapine (12 weeks) led to additional benefits by improved results (either 
newly or further improved) for the continuation group on most tests (i.e., 17 tests vs. eight 
tests for the switch group). Patients from the placebo group, who received open label 
mirtazapine for the 6-week extension achieved similar results as those in the mirtazapine 
group at the end of their initial 6-week period (i.e., six of the 21 parameters improved) This 
was the first period of active mirtazapine treatment for the placebo group, and their 
improvement was similar to the initial mirtazapine group (i.e., eight of the 21 parameters 
improved).  
 
Overall, the open label design of the extension phase did not seem to further increase the 
performance levels. This means a low rate of placebo response or regression to the mean, or 
both. The weak placebo effect was actually expected in this chronic, clinically stable 
population.  
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A 12-week period of mirtazapine treatment resulted in a better neurocognitive outcome 
than the 6-week mirtazapine treatment, as evaluated by Stroop Dots time and TMT-B 
(number of mistakes). Both tests are associated with general mental speed and attention 
control, and executive functions. This could mean that the neurocognitive effects of 
mirtazapine are principally related to attention and executive functions, and thus may also 
have desirable effects on the functional outcome. 
 
Results of prolonged treatment replicate our previous findings (Joffe et al. 2009; Studies I 
and IV). Thus, to the best of the author’s knowledge, the neurocognition data for add-on 
mirtazapine in schizophrenia reported until now are encouraging, aside from a study by Berk 
et al. (2009), which was of shorter duration. These results might also indicate that 12-week 
mirtazapine add-on to antipsychotic treatment results in additional neurocognitive 
improvements when compared to shorter duration of treatment. 
 
In Study I, mirtazapine was more effective than placebo during the first six weeks of 
treatment, according to the Block Design and Stroop Dots. However, the Block Design results 
did not differ any longer between the  6-week and 12-week treatments, indicating that the 
neurocognitive function measured by the Block Design had reached its maximum after six 
weeks of mirtazapine treatment, with no supplementary benefit after extended treatment. 
In contrast, Stroop Dots results continued to improve after the 12 weeks of mirtazapine 
treatment. Moreover, an improvement on TMT-B scores appeared only during the 
continuation treatment (i.e., the 6-week extension phase). Thus, it seems that some aspects 
of neurocognition may require less time to achieve noticeable changes while other changes 
may develop slower, as with antidepressants. 
 
All three tests; i.e., Block design, Stroop Dots and TMT-B are somehow associated with 
attention and executive functions, even though Block Design predominantly measures visuo-
spatial ability. Stroop Dots and TMT-B measures that improved after the 12-week 
mirtazapine treatment, compared to the 6-week treatment, are strongly associated with 
general mental speed/attention control and executive functions which, show an clear 
association with work performance, normal activities of daily life, outpatient service 
utilization (McGurk et al. 2004; Velligan et al. 2000), and general treatment success (Bowie 
and Harvey 2006; McKee et al. 1997). 
 
Above all, adjunctive mirtazapine enhanced neurocognition in long term patients, who were 
generally difficult to treat and whose neurocognitive decline tended to be even more 
profound and more detrimental to functional outcome than in the earlier stages of their 
illness (Harvey et al. 1998; Medalia and Richardson 2005; Spaulding et al. 1999). 
 
Even though neuropsychological domains are not directly localized to specific brain regions 
or biochemical pathways in cortex, both attention and executive functions have mostly been 
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attributed to the frontal areas (Pantelis et al. 2005). Mirtazapine, as well as some SGAs have 
strong antagonist properties to alpha 2-adrenergic receptors, which may enhance 
dopaminergic transmission in the frontal cortex (Gobert et al. 1998; Millan et al. 2000). 
  
 
Effects of add-on mirtazapine on clinical symptoms in schizophrenia  
  
 It has been reported earlier, from another part of this study, that clear-cut differences in all 
PANSS subscales and a large effect size of 1,00 (CI95% 0,23-1,67) on the PANSS total scores 
resulted from mirtazapine treatment when compared with a placebo in both within group 
and between group analyses during the double-blind phase (Joffe et al. 2009). In the open-
label phase, patients who switched to mirtazapine treatment demonstrated a clinical 
improvement in the same manner as their mirtazapine-treated counterparts in the double-
blind phase. Prolonged treatment with mirtazapine led to more prominent improvements in 
clinical parameters than short-term treatment. A trend towards improvement was seen in all 
measured parameters, therefore providing more evidence of mirtazapine’s beneficial effect 
on schizophrenia symptoms.  
  
As in the case of neurocognitive enhancing effects, the effect of mirtazapine on clinical 
symptoms may be explained by its unique receptor profile. Concerning the influence on 
negative symptoms, there are several possible mechanisms of action that may explain 
mirtazapine’s beneficial effect.  Blockade of central 5-HT2a receptor results in a number of 
effects on dopaminergic activity in the mesocortical, mesolimbic, and nigrostriatal areas of 
the brain, and it has been demonstrated in several preclinical studies that a combined 5-
HT2a and D2 receptor inhibition may have a stimulating effect on the mesocortical pathway 
of the frontal cortex, thus increasing dopamine in this area (Volonté et al. 1997; Kuroki et al. 
1999; Rollema et al. 2000). This effect is highly selective, with no simultaneous stimulation of 
dopaminergic neurotransmission in the striatum (Bonaccorso et al. 2002). A dopamine 
deficit in the medial PFC area is known to underlie the negative and cognitive symptoms of 
schizophrenia (Howes and Kapur 2009), and thereby such a drug combination may lead to 
better treatment outcomes that have a diminished risk for EPS (Meltzer et al. 2003). 
Mirtazapine also has indirect agonistic effects on 5-HT1a receptors, which may also explain 
at least part of its efficacy on negative symptoms. The 5-HT1a receptor may also be involved 
in the manifestation of negative and cognitive symptoms of schizophrenia (Kishi et al. 2011). 
Direct or indirect agonism of 5-HT1a receptors are a common characteristic for the majority 
of SGAs (Meltzer 2013), and combined with 5-HT2a blockade could deliver better efficacy on 
negative symptoms when compared to FGAs. Another preliminary hypothesis for the 
efficacy of add-on mirtazapine on negative symptoms may be due to its antagonism of 5-HT3 
receptors.  For example, adding the 5-HT3 blocking agent ondasetron to haloperidol 
improved negative symptoms, the general psychopathology and cognitive functions in 
patients with chronic schizophrenia (Zhang et al. 2006).  
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The beneficial effect of add-on mirtazapine on the positive symptoms of schizophrenia was 
more surprising than its effect to negative symptoms. Patients in this study were treated 
with FGAs, which are potent antipsychotics for treating positive symptoms, because of their 
antagonism of D2 receptors (Yilmaz et al. 2012). 
  
The preclinical and clinical data indicate that alpha-2 inhibition enhances the antipsychotic 
effects of D2 blockade (Choi et al. 2010). In a preclinical study (Wadenberg et al. 2007), the 
alpha-2 antagonist idazoxan enhanced the therapeutic effect of haloperidol and olanzapine 
combined. This finding was supported by a preclinical study by Marcus et al. (2010), in which 
idazoxan improved the efficacy of risperidone and enhanced both dopaminergic and 
glutamatergic neurotransmission in the PFC. In addition, inhibition of the histamine H1 
receptor, a shared mechanism of action for mirtazapine and clozapine, may also contribute 
to the antipsychotic effects of mirtazapine (Mancama et al. 2002).  
 
  
Main limitations of the study 
  
Although our sample size was one of the largest add-on mirtazapine trials to date, this 
relatively small sample limits the ability to draw definite conclusions for the clinical 
treatment of schizophrenia. However, the detriments of sample size in this study were 
balanced by the low discontinuation rate, the controlled design of the first phase, the 
desired and clear effect observed in chronic, difficult-to-treat patients with schizophrenia, 
consistency of mirtazapine-induced changes across a range of parameters and the time-span 
and, finally, the extended longevity of the intervention.  
 
The size of the open label design of the second phase apparently did not suffer from sample 
size, as the observed effect of the initial exposure to mirtazapine in the double-blind and 
open label phases did not differ. Yet, one could argue that observed neurocognitive benefits 
were due to practice effects (see Goldberg et al. 2010), especially in the open-label phase. 
However, there is some evidence to suggest that the practice effect could be small in 
relatively old, chronic FGA-treated patients with schizophrenia (as in our study), and that 
FGAs could even suppress the practice effect (Harvey et al. 2005). 
 
During the past years, the MATRICS CCB has become the golden standard in 
psychopharmacological studies of neurocognition in schizophrenia (Nuechterlein et al. 2008, 
Buchanan et al. 2011). Though the use of the MATRICS CCB would be undoubtedly desirable 
in this study, the consensus on this test battery was not achieved by the time of our trial. 
Moreover, all components of the MATRICS CCB had not been yet validated in Russian, nor 
were there normative data from the Russian population for all tests. For the same reason, 
composite scores could not be calculated in this study, which limits the comparability of 
these findings with to those in other studies. Nonetheless, all tests applied in the current 
trial were verified neuropsychological instruments that are used internationally (Lezak 1995; 
 
 
 
68 
  
Szöke et al. 2008). This study did not explore potential economic health aspects of the 
intervention, yet both FGAs and mirtazapine are now available as generic products, and such 
treatment would obviously be cost-effective. 
 
 
Implications for future research 
 
Further neurocognition studies with adjunctive mirtazapine in patients with schizophrenia 
should: 1) comprise larger study samples; 2) extend over a longer time span that elucidates 
whether or not some additional improvements could be achieved with prolonged treatment; 
3) also investigate treatments with SGAs, 4) apply MATRICS CCB as a verified test battery, 
and 5) include both functional and economical health outcomes. 
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Summary?and?Conclusions??
 
 
1. Mirtazapine treatment was better than placebo in the neurocognitive domains of 
visual-spatial ability and general mental speed/attention control, as assessed by 
Block Design and Stroop Dots during the 6-week double-blind phase. Adjunctive 
mirtazapine treatment might also be an effective short-term option as a 
neurocognitive enhancer for FGA-treated schizophrenia patients with an initial 
inadequate treatment response. 
 
2. Mirtazapine treatment demonstrated a perceptible and independent direct 
beneficial effect on the Block Design-measured visuo-spatial functioning. This 
neurocognitive enhancing effect was mediated through significant changes in 
positive, depressive symptoms and symptoms of parkinsonism, but not in negative 
symptoms. Higher doses of FGAs, longer durations of illness and lower initial Block 
Design scores also predicted this effect. Mirtazapine may have both direct and 
indirect influence on visuo-spatial functioning in FGA-treated schizophrenia patients 
with sub-optimal treatment response. 
 
3. During the 6-week extension phase, patients who had previously received six weeks 
of mirtazapine and those on placebo both showed significant improvement on 
several neurocognitive tests. Twelve-week mirtazapine treatment demonstrated 
better neurocognitive outcome than just six weeks of mirtazapine treatment, as 
evaluated by Stroop Dots time and TMT-B, number of mistakes, which are associated 
with general improvement in mental speed/attention control and executive 
functions. Twelve-week mirtazapine add-on to antipsychotic treatment indicated 
additional neurocognitive improvements of just six weeks, which demonstrates a 
progressive therapeutic effect. 
 
4. Patients who were on mirtazapine during both the 6-week double-blinded and the 6-
week open phases demonstrated greater improvement in positive symptoms than 
those who received mirtazapine during open-label extension phase only. During the 
6-week open-label phase, significant improvements on several clinical parameters of 
the PANSS total score were observed. Mirtazapine might have an additive 
antipsychotic effect in FGA-treated schizophrenia. The generalizability of these 
results is limited by the small sample size. 
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APPENDIX I. INFORMATION FOR A PATIENT AND INFORMED CONSENT (ENGLISH 
VERSION). 
 
 
Information for a patient. 
 
Introduction. 
Dear ..................................................................................... 
 
You are invited to participate in a study entitled “Efficacy of add-on mirtazapine on the clinical and 
neuropsychologic parameters in schizophrenic patients who are currently treated with conventional 
antipsychotics – a double-blind placebo-controlled trial with an open-label extension phase”. This 
study is a collaborative scientific project between Russian and Finnish medical researchers. Please 
read this information and ask any questions that you may have before you agree to be involved into 
the study. 
 
The purpose of the study. 
During this study, a medicine called mirtazapine will be added to you current treatment. Mirtazapine 
is an antidepressant that has been used extensively for a long time in clinical practice in the majority 
of the European countries, in the USA, Canada and Russia. The main indication for the use of 
mirtazapine is depression (long-lasting and profound decrease in mood and interest in life, fatigue, 
feeling of apathy, weakness, sleep and appetite disturbances). The disease you are suffering from is 
often accompanied to some extent with depressive symptoms, and additional use of antidepressants 
is common in clinical practice. The mechanism of action of mirtazapine differs from that of the most 
other antidepressants. This difference supposes that this medicine is able to alleviate the depressed 
mood symptoms, and make your current medication more effective. Mitrazapine can also decrease 
possible side effects of your basic medication, such as unpleasant feelings in the muscles, tremor, 
irritability, feeling of rigidity or weakness, or concentration difficulties. The addition of mirtazapine 
will probably enable a decrease in the dosage of your basic medication. Supposedly, some properties 
of mirtazapine will improve the thought process, attention and memory, and increase your general 
level of functioning. The study you are invited to participate in will make the preliminary information, 
which the above assumptions are based upon, more accurate. 
 
How the study will be conducted. 
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For the first 6 weeks of the study, after the appropriate and comprehensive medical examination of 
your health, you will be prescribed a new medication – either mirtazapine, or the so-called ‘placebo’ 
– medicine, which looks like mirtazapine but doesn’t contain any pharmacologically active 
substances. Neither you, nor your doctor will know which medicine you will receive, but you will be 
provided with this information as soon as the whole study is over; i.e., when all the patients have 
completed their participation, and the data received during the study has been analyzed. During the 
second 6 weeks, placebo will not be administered, and all patients will receive mirtazapine. 
Mirtazapine will be administered in a recommended effective dose, once daily before bed. The 
capsules or tablets must be swallowed wholly, without grinding or chewing. 
Your physician will possibly decrease the dosage of your basic medication in the second 6-week 
period of the study. Altogether, you will receive the study medication during 12 weeks (about 3 
months).  
 
Procedures of the study. 
During the study your physician will examine you with certain regularity. In total, 10 assessments of 
your mental and physical health will be performed. These visits by your physician may differ from the 
ordinary assessments that you are used to. They may include psychiatric and psychological testing 
(sometimes rather time consuming) and both clinical and laboratory tests; such as ECG, blood and 
urine analyses. 
 
Potential risk due to the participation in the study. 
As all effective medicines, mirtazapine can cause side effects in some patients, such as dry mouth, 
sleepiness, an increase in both appetite and body weight. However, these symptoms are rare, usually 
mild and most often disappear without any specific intervention during the continuation treatment 
with mirtazapine. Your physician will monitor your health condition carefully during the treatment 
period, with regular assessments of your physical and mental state. 
This study can present some other inconvenience: the participation in the study requires regular 
visits to a physician and each visit takes, at the average, more time than the ordinary visit to a 
physician. You will have to follow the dosing schedule very carefully, and not forget to return all 
unused tablets to your physician. 
 
The expected benefit. 
You can benefit from this study: the symptoms of your disease can improve or even disappear; you 
can experience improvements in memory, attention and information processing. In case you have 
had symptoms of depression, or suffered from side-effects of your basic medicine, these problems 
may also improve or even disappear. It is possible that during the treatment with mirtazapine you 
will need a smaller dose of your basic medicine. Your health condition will be monitored during the 
treatment very carefully, and you will see your physician regularly. In addition, your participation in 
this study may eventually help a large number of other patients for whom, supposedly, a safe and 
effective method of treatment is being developed. 
 
How to contact your physician. 
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If you experience any symptoms of worsening your health condition (physical or mental), you should 
contact your physician immediately, by using the phone number that he or she will give you, or 
contact the physician on call at 74-35-60.  
 
Additional information concerning the study. 
Your participation in this study is completely voluntary. You have the right to refuse participation at 
any time during the study, without any negative consequences for your treatment. In this case, you 
will be prescribed ordinary treatment. From the point of view of the study it is very important, 
however, to have as large a number of patients as possible to complete the full course of treatment. 
If you decide to withdraw from the study, it is desirable that you meet your physician for the final 
assessment as soon as possible. 
The participation in this study is based on the principle of mutual confidence, and your physician will 
guarantee that your anonymity is maintained. This means that your name will be seen only in your 
medical record, as with any usual treatment. No information will be disclosed and your identity will 
only be recorded in the study materials. In some special circumstances, however, this information 
may be required by local, federal or international authorities who monitor the quality and ethical 
issues of clinical studies. An open and diligent cooperation between you and your physician is 
crucially important for the successful progress of the study. 
 
Please feel free to ask any questions you may have, especially if there is a word or phrase that you do 
not understand. After you have attentively read this information, you will be asked to sign THE 
INFORMED CONSENT FORM (see below). 
  
 
 
 
 
93 
  
THE INFORMED CONSENT FORM. 
 
 
I,   _________________________________________________, born  19 _____   
 (surname, name, second name) 
have had enough time to learn about the information concerning the study and the investigational 
medicine. I have a full understanding of this information, I am aware of the study purpose, its 
duration and conditions of my participation in it. I am aware of the expected benefit from the 
treatment, as well as its possible side-effects and potential risk to my health. I have received the 
answers to all the questions concerning my participation in the study. 
With this statement I confirm my voluntary consent to participate in the study “Efficacy of add-on 
mirtazapine on the clinical and neuropsychologic parameters in schizophrenic patients treated with 
conventional antipsychotics – a double-blind placebo-controlled trial with an open-label extension 
phase”. 
I have the right to withdraw from the study at any time. 
 
 
«______»  _________________________ 200__ . 
 
Physician _____________________________________________ 
(surname, name, second name) 
 
Institution_______________________________________________ 
(name) 
The signature of the patient or his representative        _______________ 
The signature of the physician  _________________________________ 
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APPENDIX II. INFORMATION FOR A PATIENT AND INFORMED CONSENT (RUSSIAN 
VERSION). 
 
 
???????????????????????. 
 
????????. 
????????????????(-??)...................................................................................., 
 
????????????????????????????????????????????? «????????????????????? 
??????????????????????????????????????????????????????????????? 
????????????????????????????????????????? ?????????? – ?????????????? 
????????????????????????????? «????????» ?????». ??????????????????????????? 
?????????????????????????????????????????? ????????. ??????????, ????????????? 
???????????????????????????????????????????????, ???????????????????????????????? 
??????????????????????. 
 
?????????????????. 
??????????????????????????????????????????????????, ????????????????????????? 
??????, ??????????????? ?????????. ?????????? – ??????????????????????????????? 
?????????, ????????????????????????????????????????????????????????????????? 
??????, ??????????????, ??????????????. ????????????????????????????????????? – ??? 
????????? (?????????????????????????????????????????, ??????????? ????, 
????????????, ???????????????????, ????????, ????????????????????????). ???? 
?????????????????????????????????????????????????? ????????????????????????, ? 
???????????????????????????????????????????????????????????????????????? 
????????????????????. ????????????????????????????????????????????????????? 
???????????????????????????????????. ??????????????????????????????????, ???????? 
????????? ?????????????????????????????????????????????, ????????????????? 
????????????????????????????????????, ?????????????????????????????????????? 
????????, ???????????????????????????????? ?????, ?????, ?????????????????, 
?????????????????????????????????, ??????????????????????????. ??????????? 
?????????????????????, ????????, ?????????????????????????????????????????. 
????????????????????, ???????????????????????????????? ?????????????????????? 
????????, ?????????????????, ???????????????????????????????????????????????? 
????????????. ????????????, ????????????????????????????????????, ???????? 
?????????????????????????????????????????????, ?????????????????????????????? 
?????????????????. 
 
??????????????????????????????????. 
???????? 6 ???????????????????, ??????????, ???????????????????????????????????? 
????????????????????????????????????????????????????????, ?????????????????? 
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???????????????????????? – ????? ?????????, ??????????????????????????? – 
?????????, ??????????????????????????? ?????? ?????????, ?????????????????????? 
?????????????????????????????????. ?????, ??????????????????????????, ????????????? 
???????????????????????????, ????????????????????????????????????????????????? 
????????????????????????????, ???????, ????????, ???????????????????????????????? 
???????, ??????????????????????????????????????????. ????????????? 6 ?????? 
????????????????????????????, ?????????????????????????????? ?????????. ?????????? 
?????????????????????????????????????????????????? (1 ????????????????????? 
?????). ????????????????????????????????????????????????, ????????????????? 
??????????????. 
?????????????????????????????????????, ????????, ?????????????????????????????? 
???????????????????. ??????????????????????????????????????????????????????? 12 
?????? (??????????????????).  
 
??????????????????????. 
????????????????????????????????????????????????????????????????????? 
????????????????????????????????????????????????????????? – ?????????????????, 
??????????. ???????????????????????????????????????????????????????????????????? 
????????????????????????????????????????????????????????????????????? 
?????????????????????? (??????????????????????????????), ????????????????????? 
?????????????????????????, ?????????????????????????? ???, ???????????????????.   
 
??????????????, ???????????????????????????????????. 
???????????????????????????????, ??????????????????????????????????????????????? 
????????????????, ????????????????????????, ??????????????????????????????????? 
??????????? ?????????. ????????????????????????, ??????, ??????????????, ?? 
????????????????????????????, ??????????, ????????????????????????????????????? 
???????? ???????????. ???????????????????????????????????????????????? 
??????????????????????????????, ???????????????????????????????????????? 
??????????????????????????????????. 
???????????????????? ???????????????????????????????????????????????? 
??????????: ??????????????????????????????????????????????????????????, ???????? 
??????????????????, ?????????, ??????????????, ?????????????????????????. ??? 
??????????????????????????????????????????????????????????????????????, ?? 
??????????????????????????????????????????????????????????????. 
 
????????????????. 
???????????????????????????? ????????????????????: ??????????????????????????? 
????????????????????????????????????, ???????????????????????????????????, 
????????????????????????????????. ????????, ???????????????????????????????? 
??????????????????????????????????????????????????????????, ??????????????????? 
????????????????????????????????????????????. ????????????, ???????????????? 
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???????????????????????? ???????????????????????????????. ?????????????????????? 
???????????????????????????????????????????????????????????, ??????????? 
????????????????????????????????????????????. ??????????, ????????????????????? 
????????????? ????????????????????????????????????????????????, ???????????, ??? 
??????????????, ??????????????????????????????????????????????? ????????????. 
 
??????????????????????. 
?????????????????????????????????????????????????????????????????? (??? 
???????????, ??????????????????), ?????????????????????????????????????????????? 
??????, ???????????, ??????????????????????????????????, ?????????????????????? 
??????????? 74-35-60.  
 
?????????????????????????????????????????. 
?????????????????????????????????????????????. ????????????????????????????? 
????????????????????????????????????, ???????????????????????????????????????????? 
???????????????????????????, ?????????????????????????????????????????. ??????? 
???????????????????, ?????????? ?, ?????????? ????????????????????????????????? 
???????????????????????????????????????????. ????????????????????? ???????? 
???????????????????????????????, ???????? ?????????, ???????????????????????? 
?????????????????????????????????????????????????????????????. 
????????????????????????????????????????????????????????????????, ?????????? 
?????????????????????????????????????????????????. ????????????, ???????????? 
???????????????????????????????????????????????????????????????????????????, ??? 
??????????????????????????????. ????? ???????, ??????????????, ??????????? 
????????????????????????, ???????????????????????????????????? ?????????. ??? 
????????????, ??????, ?????????????????????????????, ????????????????????????? 
???????????????????????, ???????????????????????????????????????, 
??????????????????????????????????????????????????????????????????? 
????????????. ?????????????????????????????????????, ????????????????????????? 
?????????????????? ???????????????????????????????????????. 
 
??????????, ?????????????????????, ??????????????????????, ????????, ???????? 
????????????????????????????????????? ????. ??????????, ????????????????????????? 
???????????????, ????????????????????????????????????????????? ??????????? 
???. ????). 
 
 
????????? ???????????? ???????????. 
 
 
??????,  _________________________________________________  19_____ ?. ?.  
   ????????, ???, ????????) 
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???????????????????????, ????????????????????  ???????????????????????????????? 
?????????????????????. ??????????????????????????????????, ???????????????????? 
????????????, ????????????????????????????????????????????????????, ?????????????? 
?????????????????????????????????????????????????????????????????????. ????????? 
?????????????????????????? ???????????. 
???????????, ??????????????????????????????????????????????????????????? 
???????????????????????? «?????????????????????? ???????????????????? 
?????????????????????????????????????????????????????????????????????????? 
???????? ?????????? – ???????????????????????????????????????????? «????????» 
?????».. 
??????????????????????????????????????????????????????????. 
 
 
«______»  _________________________ 200__ ?. 
 
????????????? _____________________________________________ 
????????, ???, ????????) 
?????????? _______________________________________________ 
?????????????) 
????????????????????????????????????????????????  _____________ 
 
???????????????????????  ___________________________________ 
 
 
 
 
 
 
 
 
 
